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1. Abstract 
The immune system has to manage the critical decision to induce either immunity or 
tolerance. Cells that take part in the regulatory processes of the immune system are 
amongst others antigen presenting cells (APCs), especially dendritic cells (DCs) and 
macrophages (MΦs). Recently, it was shown that the mannose receptor (MR), known as 
an endocytic receptor expressed by specific APCs, is responsible for the induction of T 
cell tolerance. Under non-inflammatory conditions, the MR expressed by DCs can bind 
to CD45 on CD8+ T cells. The interaction of MR and CD45 induces the inhibition of 
CD45 phosphatase activity. Thereby, transcriptional T cell re-programming and up-
regulation of CTLA-4 in T cells are initiated resulting in T cell tolerance.  
As CD45 is not only expressed by T cells but by all hematopoietic cells including APCs, 
the aim of this thesis was to investigate a putative influence of the MR on APCs by 
interaction with CD45. 
 
We could show that GM-CSF induced, bone marrow derived APCs (BM(GM-CSF) cells) 
express the lowest molecular isoform of CD45, CD45R0, that interacted with a 
recombinant MR construct comprising the CR, FN II, and CTLD1-2 domains of the MR 
(FcMR). This interaction impaired CD45 phosphatase activity in BM(GM-CSF) cells and 
altered intracellular signalling pathways. The capacity of APCs to stimulate antigen-
specific T cells was altered by binding of FcMR to CD45. Antigen-specific T cells primed 
by FcMR pre-stimulated APCs showed reduced cytokine secretion of CD4+ T cells 
determined by IFN-γ levels and diminished cytotoxic activity of CD8+ T cells, although, 
proliferation of T cells remained unaffected. 
In addition, the application of supernatant containing soluble mannose receptor (sMR), 
that is shed by MR-positive cells, to stimulate BM(GM-CSF) cells also decreases CD45 
phosphatase activity but in contrast supports an immunstimulatory phenotype of 
activated antigen-specific T cells. 
Recently, sMR was found to be highly elevated in several diseases. Here, we could show 
enhanced sMR serum levels after high-fat died or obesity in mice and human, 
respectively, pointing out a direct correlation of sMR expression and inflammatory 
metabolic processes. 
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2. Introduction 
2.1. The immune system 
The human body has to constantly manage the invasion of a multitude of different 
microbes e.g. bacteria, viruses, fungi, and parasites, to maintain a certain state of health 1. 
Thereby, discriminating between healthy and infected cells, while pathogens evolve and 
adapt rapidly to circumvent the detection and neutralization by the immune system, is 
the main challenge for the host organism 1–3. Due to this evolutionary pressure, a 
complex network of interacting cell types with various effector functions has developed 
3. Two different systems, the innate and the adaptive immune system, can be 
distinguished in regard to speed and specificity of their responses 4.  
2.1.1. The innate immune system 
An innate immune system is found in all multicellular organisms 3. It acts at early stages 
of infection 5 when pathogens break through the physical and chemical barriers of the 
skin. The innate immune system is composed of different cell types (e.g. neutrophils, 
macrophages, and natural killer cells) 4,6 as well as immunoregulatory components (e.g. 
the complement, cytokines like interferons, and acute phase proteins) 4,7. It reacts fast 
and thereby prevents antigen-spreading but it is antigen-nonspecific 6. Cells of the innate 
immune system recognize pathogens by germline-encoded pathogen recognition 
receptors (PRRs) 1,3,5. PRRs recognize highly conserved structures associated and shared 
by a large group of pathogens 1,5. These so-called pathogen associated molecular patterns 
(PAMPs) differ between microbes. E.g. gram-positive and gram-negative bacteria are 
recognized by bacterial wall components like LPS 3,6,7 or by bacterial DNA with 
unmethylated CpG motifs 1. In contrast, viruses are recognized by double-stranded RNA 
3,6 and yeasts by carbohydrates like cell wall mannan 3,6. 
2.1.2. The adaptive immune system 
An adaptive immune system is a hallmark of higher vertebrates 4. It consists mainly of B 
and T cells bearing high affinity receptors, which enable the host organism to the 
antigen-specific recognition and elimination of pathogens 4,5 but also depends on antigen 
presenting cells (APCs), especially dendritic cells (DCs) and macrophages (MΦs), at the 
interface of innate and adaptive immune system 4. The antigen-specific receptors of B 
and T cells are not germline-encoded but rather a result of random gene arrangement 
Introduction 
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and splicing leading to a repertoire of over 1010 antibody specificities 4. The APCs take up 
pathogens at the side of invasion, migrate to secondary lymphoid organs, where the 
clonal selection and expansion of B and T cells is carried out, and present pathogen-
related antigens on their surface to activate antigen-specific T cells 3–5. The clonal 
expansion is the explosive increase in lymphocytes where all progeny bear the same 
antigen specificity. Due to the whole activation cascade, the adaptive immune response is 
time-consuming 4 and has the ability of an immunological memory 6. DCs play a unique 
role because they are able to prime naive T cells and thereby induce the primary immune 
response 6,7. 
2.2. Dendritic cells 
DCs develop from progenitors in the bone marrow. As precursors they circulate through 
blood, lymphatics, and lymphoid tissues. Some DCs remain in peripheral tissues, where 
they have a high endocytic and phagocytic capacity important for example after tissue 
damage 6–8. Once danger signals like microbial products, infectious agents, or 
inflammatory products are recognized by DCs, they start to mature 8,9. This maturation is 
crucial for the initiation of immunity 8. Surface molecules like major histocompatibility 
complex (MHC) and costimulatory molecules (cluster of differentiation (CD) 40, CD80, 
CD86) for antigen presentation and T cell activation are upregulated whereas endocytic 
and phagocytic capacity is downregulated. During maturation, DCs migrate to secondary 
lymphoid organs where they present antigens and thereby activate CD4+ and CD8+ T 
cells 7,8. Afterwards, T cells are able to leave the lymphoid organs, migrate to the site of 
infection and start to eliminate invading pathogens (see Figure 1). 
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Figure 1: Initiation of adaptive immunity by the example of CD8+ T cells. Immature DCs capture 
and process antigen in peripheral tissues if pathogens enter the body. Afterwards, DCs start to mature 
while they migrate to secondary lymphoid organs, that means upregulation of MHC and costimulatory 
(CD40, CD80, CD86) molecules and downregulation of endocytotic capacity. In the lymphoid organ, 
DCs activate antigen-specific naïve CD8+ T cells. Activated T cells start to proliferate and leave the 
secondary lymphoid organ to eliminate pathogens in the peripheral tissues. 
DCs are initiator as well as modulator of the adaptive immune response 8. Multiple 
subsets of DCs exist generating a heterogeneous cell population 7. Each DC subgroup 
expresses distinct surface molecules and secretes different cytokines 9. Thereby, DCs can 
not only induce immunity but also confer to the host’s tolerance preventing 
autoimmunity 6,8. The immune stimulatory and inhibitory potential of DCs contributes to 
disease pathogenesis (e.g. organ transplantation, allergy, and autoimmunity) 7. Therefore, 
DCs are of special interest as targets for clinical trials 8. 
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2.3. Antigen presentation 
To activate naïve T cells, antigens need to be processed and presented on MHC 
molecules by APCs 8. The process of antigen presentation comprises the uptake, 
degradation, and loading of antigen on MHC molecules 9. 
APCs incorporate particles or soluble antigens by phagocytosis or macropinocytosis, 
respectively. Furthermore, they express a wide range of surface receptors e.g. Fc-
receptors or C-type lectins like the mannose receptor (MR) for receptor-mediated antigen 
uptake 7,9. Both, endogenous and exogenous antigens are degraded by the proteasome in 
the cytosol or by enzymes via the endocytic and phagocytic pathway 7,10. 
Proteins degraded by proteasomal proteolysis are loaded onto MHC class I molecules in 
the endoplasmic reticulum (ER). The antigens result from intracellular proteins such as 
viral proteins, as well as from phagocytosis 10. A process called cross-presentation also 
enables the uptake, degradation, and loading of extracellular antigens on MHC I 
molecules in stable early endosomes (SEE) or the ER after receptor-mediated 
endocytosis e.g. by the mannose receptor (see Figure 2). This plays an important role 
for the recognition of transplant- and tumor-derived antigens as well as antigens from 
viruses that cannot infect APCs 8,11. Only MHC I-bound peptides are recognized by 
cytotoxic CD8+ T cells and this recognition is essential for their activation 4,7,8.  
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Antigens of lysosomal proteolysis are loaded onto MHC II molecules. These peptide-
MHC complexes are recognized by CD4+ T helper cells 4,7,8. Exogenous antigens taken 
up by macropinocytosis and endocytosis are delivered to late endosomal structures but 
also endogenous antigens can be transported to endosomal compartments by 
macroautophagy and chaperone-mediated autophagy 10,12 (Figure 3). 
Figure 2: Antigen processing for MHC class I presentation. Intracellular proteins or antigens from 
phagocytosis are degraded in the cytoplasm by the proteasome, transported to the ER and loaded onto 
MHC I molecules. Peptide/MHC I complexes are transmitted to the cell surface where they can activate 
CD8+ T cells. Exogenous antigens taken up by receptor-mediated endocytosis e.g. by the mannose 
receptor, are transported to stable early endosomes (SEE) from where they are translocated to the 
cytoplasm and also degraded by the proteasome. Peptides are reimported in the SEE or in the ER for 
loading onto MHC I molecules and the MHC I/peptide complexes are transported to the cell surface. 
This process is called cross-presentation. 
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Figure 3: Antigen processing for MHC class II presentation. Antigens for MHC II presentation are 
generated by proteolysis in lysosomes and reach these compartments through different pathways. (i) 
Exogenous antigens captured by phagocytosis or macropinocytosis are transported to lysosomes. (ii) 
Endogenous antigens are engulfed by an isolated membrane generating an autophagosome. These 
vesicles readily fuse to lysosomes. (iii) Endogenous proteins can be recognized by heat shock proteins 
that guide antigens for membrane translocation and entry into lysosomes via chaperone-mediated 
autophagy (CMA). In lysosomes, proteases facilitate the digestion of captured antigens. These late-
endosomale structures fuse with MHC class II-rich compartments (MIIC) coming from the ER. Peptides 
are loaded onto MHC II molecules, transported to the cell surface and activate CD4+ T cells.   
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2.4. Three signals for T cell activation 
The productive activation of naïve T cells needs three signals from APCs. 
First, the recognition of MHC/peptide complexes on the cell surface of APCs by 
antigen-specific T cell receptor (TCR) of T cells 3,7. 
Second, the interaction of costimulatory molecules expressed by APCs (CD40, CD80, 
CD86) with ligands and counterreceptors on T cells (CD28, CD40L) 1,3,7. Off note, the 
presentation of antigens in the absence of costimulatory molecules leads to the 
permanent inactivation of T cells 3. 
Third, cytokines released by APCs (e.g. interleukin (IL)-12) can induce different classes 
of immune response and are critical for T cell differentiation 7 (see Figure 4). 
 
 
Figure 4: Three signals crucial for T cell activation. Three signals are important for full activation of 
T cells. Signal one is the binding of MHC/peptid complex to T cell receptor (TCR). Signal two is the 
interaction of costimulatory molecules (e.g. CD80/86) of APCs with its counterreceptor of T cells (e.g. 
CD28). For signal three APCs release cytokines (e.g. IL-12) that bind to cytokine receptors (e.g. IL-12R) 
on T cells. 
The combination of the three signals leads to the clonal expansion and differentiation of 
T cells into effector and memory cells 13.  
2.5. Initiation of T cell activation 
To maintain the healthy state of the body a proper function of T cells is essential. This 
function is mediated by a direct cell-cell interaction or via the secretion of various 
cytokines. Deviations in the function of T cells lead to immunological diseases e.g. 
autoimmunity, allergies, or immunodeficiencies 14. 
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2.5.1. CD4+ T cell effector mechanisms 
CD4+ T helper cells recognize foreign antigens presented by MHC class II molecules on 
APCs 4. Once activated, CD4+ T cells produce cytokines important for activating other 
cells of the cell-mediated immune response, e.g. MΦs or B cells. Due to the function of 
CD4+ T cells to activate a wide range of effector cells, the stimulation of CD4+ T cells is 
highly controlled. Thus, only a small number of cells express MHC II molecules 4.  
The cytokine environment secreted by APCs mainly dictates the development of 
specialized effector T helper cells (see Figure 5). Depending on the production of 
signature cytokines that are secreted by effector T cells, CD4+ T cells are subdivided into 
Th1, Th2, Th9, Th17, T follicular-helper (TFH), and T-regulatory (Treg) cells 
15. All subsets 
show diverse functions. Th1 cells secrete among other IFN-γ facilitating clearance of 
intracellular pathogens. Th2 cells secrete e.g. IL-4, IL-5, and IL-13, and thereby 
promoting clearance of extracellular organisms especially parasites 15. Th17 and Treg cells 
contribute to tissue inflammation, whereas Th17 cells induce autoimmune tissue injury 
by secreting IL-17. Treg cells inhibit autoimmunity and tissue injury. Furthermore, Treg 
cells also suppress other T cell subsets by secreting IL-10 16. Th9 and TFH cell function is 
not entirely clear but the cells might contribute to both protective immunity and 
immune-mediated inflammatory diseases 15,17. 
 
Figure 5: CD4+ T cell effector mechanisms. Binding of T cell receptor to the MHC II/peptide complex 
presented by APCs activates naïve CD4+ T cells. The cytokine environment generated by APCs 
promotes the development of effector CD4+ T helper cells. Once activated, T helper cell subsets are 
identified by their signature cytokine production facilitating diverse effector functions.  
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2.5.2. CD8+ T cell effector mechanisms 
Cytotoxic CD8+ T cells are activated by peptides presented on MHC class I molecules 
which are expressed on all nucleated cells 4. Via MHC class I molecules, these cells 
present endogenous self-antigens as well as virus, intracellular pathogens, and abnormal 
tumor antigens. Cells presenting the T cell-specific pathogen-related peptide get directly 
eliminated by CD8+ T cells 4,8. The cytotoxic T cells secrete perforin and granzymes to 
penetrate the membrane and induce DNA fragmentation and cell apoptosis, respectively 
(see Figure 6). Additionally, cytotoxic T cells express Fas molecules that bind to Fas 
receptors on target cells and promote also apoptosis 4. 
 
Figure 6: CD8+ T cell effector mechanism. Binding of T cell receptor to MHC I/peptide complex 
presented by APCs in the lymph node activates naïve CD8+ T cells. Once activated, cytotoxic T cell 
(CTL) recognize infected cells by bearing foreign peptides on MHC I in peripheral tissues. CTLs secrete 
perforin and granzymes that induce DNA fragmentation and apoptosis of the target cell. Furthermore, 
the Fas/Fas ligand pathway gets activated in the target cell also leading to apoptosis. 
2.6. TCR signaling 
The activation of T cells is initiated by a signal transduction induced by binding of TCR 
to peptide-MHC complex 18. 
The TCR is a transmembrane receptor comprised of two different subunits: The α and β 
chain. In <10% of T cells the TCR is made up from a γ and a δ chain, a subgroup of T 
cells which specific function is still elusive 4. The TCR is associated with CD3 which 
consists of two ε, a γ and a δ chain and two ζ chains that are important for the 
transduction of the signal generated by ligand binding 14,19.  
After interaction of TCR with peptid/MHC complex, coreceptor CD4 or CD8 binds to 
MHC molecules and thereby brings the Src family protein tyrosine kinase (PTK) Lck 
into the proximity of cytoplasmic domains of the TCR. Lck phosphorylates 
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immunoreceptor tyrosine-based activation motifs (ITAMs) of the TCR 14 that provides 
docking sites for the SH2 domains of ZAP-70. The Syk family PTK ZAP-70 gets 
phosphorylated and activated by Lck and can then phosphorylates the adaptor proteins 
SLP-76 and LAT. This leads to the phosphorylation and activation of multiple 
downstream effectors resulting in calcium mobilization, activation of mitogen-activated 
protein kinases (MAPKs), transcriptional regulation and cytoskeletal rearrangement 
(Figure 7) 14,18,20,21. 
 
 
Figure 7: T cell receptor signaling. The T cell receptor (TCR) on T cells binds to peptide/MHC I 
complex on APCs. The interaction enables the binding of CD8 to MHC molecules whereby Lck comes in 
close proximity to TCR. Lck phosphorylates ITAMs in ζ chains of TCR whereby ZAP-70 could be 
recruited to TCR. ZAP-70 gets activated by phosphorylation through Lck and could then phosphorylates 
LAT and SLP-76. Phosphorylation of these molecules initiates downstream signaling cascades leading 
to calcium mobilization, activation of MAPKs, transcriptional regulation and cytoskeletal rearrangement.  
Introduction 
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The natural counterparts of PTKs are protein tyrosine phosphatases (PTPs). PTPs 
dephosphorylate proteins and reduce or enhance their function depending on the 
phosphorylation site and signalling context 18. The activity of Lck, the first PTK 
downstream of TCR, is highly regulated by PTPs. An inhibitory C-terminal site of Lck 
(Y505) can be phosphorylated by Csk and dephosphorylated by CD45. Furthermore, the 
PTPs LYP and SHP-1 can dephosphorylate an activating tyrosine (Y394) within the 
catalytic domain. The balance between the activities of PTPs and PTKs is responsible for 
the initiation of signalling 18. 
2.7. CD45 
CD45 is a leukocyte-specific high-molecular-weight surface glycoprotein. It covers ~10% 
of the cell surface and is, thereby, the most abundant cell surface glycoprotein in 
leukocytes. The glycosylation pattern varies between cell types and depends on 
developmental and activation state as well as differential spliced exons. The differences in 
carbohydrate structures imply a functional consequence 22. 
CD45 is encoded by 34 exons. Different isoforms are generated by alternative splicing of 
three exons (4, 5 and 6). To date, five isoforms have been detected at the protein level in 
human leukocytes. CD45 consists of a large cytoplasmic domain, a single membrane-
spanning domain and an N-terminal, external domain of variable length 22 (see Figure 
8).  
The intracellular part of CD45 has two tandemly duplicated PTPase homology domains. 
The membrane-proximal domain D1 has enzymatic activity 23 and is necessary for TCR-
mediated signal transduction shown by experiments in a CD45-deficient cell line 24. The 
function of the second intracellular domain D2 remains elusive. Some studies have 
indicated that the D2 domain might be essential for D1 PTP activity 25,26. 
The extracellular part of CD45 consists of a cysteine-rich region, three fibronectin type 
III repeats and the alternatively spliced exons 23,27. The molecular weight of CD45 differs 
between 180-240 kDa depending on the isoform.  
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The extracellular conserved part of CD45 is heavily N-glycosylated with sugars of tetra- 
and triantennary complex-type as well as poly (N-acetyllactosamine) groups and α-2,6-
linked sialic acid residues. The exterior domain has multiple sites for core 1 and 2 O-
linked carbohydrates variable modified by sialic acid. Therefore, the various isoforms 
differ in size, shape, and charge 22,23.  
A specific juxtamembrane ‘wedge’ motif seems to be involved in trans-dimerization of 
CD45 leading to inhibition of activity 18,23. An inactivating point mutation (CD45E613R) 
in the inhibitory wedge motif generates a constitutively active form resulting in an 
autoimmune syndrome resembling human systemic lupus erythematosus (SLE) 28. 
Although all isoforms show identical PTPase activity, in vitro, the isoforms homodimerize 
differently 23. 
The function of CD45 differs between leukocytes. In B cells, CD45 is a critical regulator 
of BCR signalling. In mast cells, CD45 is important in histamine degranulation after IgE 
receptor cross-linking 23 and in neutrophils CD45 influences chemotaxis 29. 
Figure 8: Structure of CD45. The protein tyrosine phosphatase (PTPase) CD45 consists of a large 
cytoplasmic domain, a single membrane-spanning domain and an external domain of variable length. 
Intracellular, the D1 domain, one of two tandemly duplicated PTPase homology domains, has 
phosphatase activity. The D2 domain is thought to be essential for D1 PTPase activity. The 
extracellular, highly glycosylated part of CD45 consists of three fibronectin type III (FN III) repeats, a 
cysteine-rich domain and three alternatively spliced exons. 
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CD45-deficient MΦs revealed a role of CD45 in integrin-mediated adhesion and in 
regulation of Hck and Lyn activity 30. 
Reduction of CD45 activity in DCs lead to enhanced adhesion due to strong cell cluster 
31,32. However, Prickett et al. (1989) showed reduced cluster stability in the presence of a 
CD45 antibody 33. Furthermore, in DCs, CD45 has a positive as well as negative effect 
on TLR-induced cytokine secretion 34–36. 
In T cells, CD45 has a pivotal role in signal transduction by acting as a positive and 
negative regulator of Src family protein tyrosine kinases (SFKs). In CD45-/- mice the 
majority of peripheral T cells are self-reactive due to hyporesponsiveness to antigen 
stimulation 37. Furthermore, CD45-deficient humans 38,39 or mice 40–42 develop a severe-
combined immunodeficiency (SCID) phenotype due to defects in thymic development 23. 
Other data of CD45-deficient mice suggest also a negative regulatory function of CD45 
43–46. CD45 can indirectly inhibit T cell function by upregulating the expression of the 
inhibitory co-receptor CTLA-4 47. Janus kinases (JAKs) are other substrates of CD45, 
which dephosphorylated by CD45 negatively regulate cytokine and interferon receptor 
activation 48–50. 
Ligands of CD45 are e.g. Galectin-1 51 or the C-type lectin MGL 52. In 1999 Martinez-
Pomares et al. published the MΦ mannose receptor (MR) as counter-receptor of CD45 
53.  
2.8. Mannose receptor (MR) 
The MR is a 180 kDa transmembrane, carbohydrate-specific PRR expressed by diverse 
subpopulations of MΦs and DCs as well as nonvascular endothelium 54,55. It is part of the 
C-type lectin family of PRRs 56 and shares the same overall structure: extracellular a N-
terminal cysteine-rich (CR) domain, a single fibronectin type II (FN) domain, and 
multiple C-type lectin-like domains (CTLDs); a type I membrane domain; intracellular a 
short cytoplasmic domain (see Figure 9).  Other members of this family are e.g. 
DEC205, phospholipase A2 and Endo180.  
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The CR region of the MR is capable to bind sulphated sugars like N-acetylgalactosamine 
57 and glycoprotein hormones like lutropin and thyrotropin 55 in a calcium-independent 
manner. Its binding capacity is enhanced by multimerization 58. The CR domain also 
binds to ligands expressed by the marginal zone metallophilic MΦs in the spleen and 
subcapsular sinus MΦs in lymph nodes 59. Investigated ligands are e.g. sulphated forms of 
sialoadhesin and CD45 53. 
The FN II domain is known for its binding of collagen. In human and mouse, MΦs 60,61 
as well as in liver sinusoidal endothelial cells 62 collagen is endocytosed through the MR. 
The MR has eight CTLDs. Nevertheless, only CTLD4 and 5 have carbohydrate-binding 
ability 55. In a calcium-dependent manner, the CTLDs recognize carbohydrates 
terminated in mannose, fucose and N-acetylglucosamine that are modified with sialic 
acid 54. 
A tyrosine-based motif in the cytoplasmic domain is required for receptor internalization 
and recycling 63,64.  
 
The MR undergoes proteolytic processing resulting in a functional, soluble form of the 
MR (sMR) 54. The sMR consist of the complete extracellular region and is generated after 
Figure 9: Structure and binding properties of MR. The MR is a type I transmembrane protein with a 
large extracellular part containing three different types of domains. A cysteine-rich (CR) domain is 
followed by a fibronectin type II (FN) domain and eight C-type lectin-like domains (CTLDs). The CR 
domain mediates the binding to sulphated N-linked carbohydrates and glycoprotein hormones like 
lutropin and thyrotropin. The FN domain binds collagen and of the eight CTLDs only 4 and 5 has 
carbohydrate-binding capacity. In a calcium-dependent manner, the CTLD 4 recognizes sialic acid-
modified carbohydrates terminated in mannose, fucose and N-acetylglucosamine. The cytoplasmic 
domain contains a motif important for endocytic function. 
Introduction 
 
 16 
cleavage by metalloproteases 65. Fungal pathogens such as Candida albicans, Aspergillus 
fumigatus and Pneumocystis carinii can enhance the production of the sMR 66,67. The binding 
capacity of sMR is still functional but recognition of sulphated carbohydrates by the CR 
domain requires protein multimerization 54. sMR is found in supernatant of MR-positive 
cells as well as in mouse 65 and human serum 68. In several diseases including sepsis, liver 
disease, and multiple myeloma, sMR is strongly elevated and, therefore sMR is seen as a 
new biomarker 68–70. 
 
The well-known function of the MR is the internalization of glycoconjugates of 
pathogenic origin as well as self-molecules. Under inflammatory conditions, 
mannosylated proteins are taken up by the MR and conducted in compartments 
specialized for cross-presentation. These SEEs allow the export of proteins to the 
cytoplasm for degradation by the proteasome and the relocation in the SEEs for loading 
on MHC I molecules. The MHC I/peptid complex is translocated to the cell membrane 
to activate antigen-specific CD8+ T cells (see Figure 2) 71. Due to this mechanism, the 
MR facilitates the immune response against pathogens.  
Under non-inflammatory conditions, the MR has also an immunregulatory function. The 
MR is expressed by a multitude of tolerogenic APCs. Its expression is upregulated by 
anti-inflammatory cytokines like IL-4 and IL-10 72,73. As it was shown by various studies, 
the MR-dependent antigen uptake can lead to tolerance. For example, the treatment of 
experimental autoimmune encephalomyelitis (EAE) mice with a soluble mannosylated 
epitope of proteolipid protein (M-PLP139-151) generates antigen-specific tolerogenic T cells 
74. Additionally, monocyte-derived DCs that are treated with an anti-MR crosslinking 
antibody secrete an anti-inflammatory cytokine profile resulting in regulatory T cells and 
T cell anergy 75. MR-expressing CD11b+CD11c- cells in the mucosa generated 
suppressive CD4+ T cells after sublingual immunotherapy (SLIT) 76. Furthermore, 
tumoral mucins that are taken up by the MR as well as anti-MR antibodies result in an 
immune suppressive cytokine profile in human tumor-associated MΦs 77. In line with 
this, systemically circulating tumor antigens processed in a MR-dependent manner by 
liver sinusoidal endothelial cells (LSECs) promote CD8+ T cell tolerance 78.  
Besides the tolerogenic properties due to MR-dependent antigen uptake, the MR can 
directly initiate T cell tolerance. The presence of MR on the surface of APCs directly 
impairs the cytotoxic activity of CD8+ T cells in vitro and in vivo. 
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Under non-inflammatory conditions, CD8+ T cells activated by APCs in the presence of 
MR display decreased cytotoxic activity and IFN-γ secretion compared to T cells 
activated in the absence of MR. These diminished effector functions are due to a direct 
interaction of the MR with CD45 on T cells. The interaction impairs CD45 phosphatase 
activity leading to an active reprogramming of T cells. The crucial step of inactivating 
CD45 enables a signalling pathway in addition to T cell receptor signalling that reduces 
the expression of Bcl-6 facilitating the up-regulation of CTLA-4. High protein levels of 
CTLA-4 in T cells activated by MR-bearing APCs lead to CD8+ T cell tolerance 79 
(Figure 10). 
 
Figure 10: MR-mediated induction of T cell tolerance in CD8+ T cells via inhibition of CD45 and 
up-regulation of CTLA-4. In the absence of the MR CD45 phosphatase of CD8+ T cells is active and 
facilitate expression of Bcl-6. Bcl-6 is a repressor of transcription and inhibits transcription of CTLA-4. 
Reduced expression of CTLA-4 enables costimulation via CD80/86 binding to CD28 and promotes T cell 
activation (left panel). In the presence of MR, MR binds to CD45 on CD8+ T cells and inhibits CD45 
phosphatase activity. Expression of Bcl-6 is inhibited that enables transcription of CTLA-4. Up-regulation 
of CTLA-4 on the surface of CD8+ T cells interrupts costimulation via CD28 and thereby, inhibits T cell 
activation (right panel). 
  
Aim of the thesis 
 
 18 
3. Aim of the thesis 
The MR in a cell-bound form is able to induce T cell tolerance by up-regulation of 
CTLA-4 in CD8+ T cells through direct binding of CD45 79. CD45 is expressed by all 
lymphocytes including antigen presenting cells (APCs) 23. APCs take part in the 
regulation of critical decisions of the immune system to induce either T cell activation or 
tolerance. We hypothesized an MR-mediated influence on the function of APCs by 
interaction of MR with CD45 on APCs. The aim of the following study was to analyse an 
effect of the MR on APC capacity.  
As a model, GM-CSF-induced, bone-marrow derived APCs (BM(GM-CSF)) were used. 
First, the expression of CD45 on these cells as well as the expressed isoform should be 
analysed. To investigate an influence of MR on APC function a recombinant mannose 
receptor (MR) construct comprising the CR, FN II, and CTLD1-2 domain of the MR 
fused to a human IgG1 Fc part (FcMR) was used. By using FcMR an interaction with 
CD45 on APCs as well as an influence on CD45 phosphatase activity should be 
investigated. Furthermore, the stimulation of APCs with FcMR should elucidate an effect 
of MR on APCs by analysing the effector function of CD4+ as well as CD8+ T cells 
activated by pre-stimulated APCs. 
Beside the cell-bound form of the MR, a soluble protein (sMR) is generated by 
proteolytic cleavage through metalloproteases 65. The secretion of sMR by BM(GM-CSF) 
cells in cell supernatant should be analysed. Additionally, this natural source of MR 
should also be used to investigate an influence of MR on APCs performing CD45 
phosphatase activity assays and effector functions of activated CD4+ and CD8+ T cells.  
This sMR is also found in the serum of mice 65 and human 68 and is strongly elevated in 
several diseases 68–70. Therefor, the levels of sMR in vivo in serum of mice fed a low-fat 
diet (LFD) or high-fat diet (HFD) as well as of lean and obese humans should be 
analysed. 
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4. Material and Methods 
4.1. Material  
4.1.1. Mouse strains 
Strain Description Background Haplotyp 
C57BL/6JCrl Wild type mouse strain C57BL/6JCrl H-2Kb 
DesTCR Transgenic mouse strain with a Kb-
specific T cell receptor (KB5.C20 TCR) 
in CD8+ thymocytes. T cells recognize 
endogenous processed peptides 
presented on H-2Kb in an allogenic 
reaction 80 
B10.BR H-2Kk 
MR-KO Transgenic mouse strain with an insertion 
of a stop-codon in exon 1 of mannose 
receptor preventing its expression 81 
C57BL/6JCrl H-2Kb 
OT-I/RAG-
KO 
Transgenic mouse strain with expression 
of an OVA257-264 CD8
+ specific MHC 
class I H-2Kb TCR 82,83 
C57BL/6 H-2Kb 
OT-II Transgenic mouse strain with expression 
of an OVA323-339 CD4
+ specific MHC 
class II I-Ab-restricted TCR 84 
C57BL/6 H-2b 
4.1.2. Cell lines 
Cell line Description Culture medium 
HEK293T Human embryonic kidney cell line immortalized 
by adenovirus type 5 DNA 85 
HEK medium 
J558L Murine BALB/c myeloma cell line transduced 
with murine GM-CSF sequence 86 
BM(GM-CSF) 
survey medium 
RMA Murine T cell tumor cell line derived from 
C57BL/6 mice 87 
T cell medium 
RMA-S Mutagenized RMA cell line with mutated TAP 
gene. Procession and expression of endogenous 
peptides on MHC class I molecules are 
impossible. 87 
T cell medium 
YBM42.2.2 Murine rat hybridoma producing anti-mouse 
CD45 antibody 88 
YBM medium 
4.1.3. Consumables 
Consumable  Company 
15 mL / 50 mL PP tubes Sarstedt 
24-well cell culture plate, flat bottom Sarstedt 
26G x 1’’ disposable hypodermic needle B. Braun 
41 µm polyamide mesh Labomedic 
6-well cell culture plate, flat bottom Sarstedt 
96-well tissue culture plate, flat bottom TPP 
BD PlastipakTM 50 mL syringe Becton Dickinson 
Bottle-top filter, 0.22 µm Corning 
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Cell culture dish 100 x 20 mm Sarstedt 
Cell culture dish 150 x 20 mm Sarstedt 
Cell scraper 25 cm Sarstedt 
EASYstrainerTM 40 µm cell strainer Greiner Bio-One 
ELISA-plate Microlon® 96W, flat bottom, high binding Greiner Bio-One 
FACS tubes, 5 mL Sarstedt 
Petri dish 92 x 16 mm Sarstedt 
Protran BA83 nitrocellulose membrane, 0.2 µm Amersham 
Rotilabor-blotting papers, 1.5 mm Roth 
Spin-X® UF 6 concentrator (50k MWCO) Corning 
T75 tissue cell culture flask Sarstedt 
WhatmanTM sterile 0.45 µm cellulose acetate membrane 
syringe 
GE Healtcare 
4.1.4. Chemicals, reagents and commercial kits 
Reagent Company 
4-Nitrophenyl phosphate disodium salt hexahydrate (4-NPP) Sigma-Aldrich 
Albumin egg (ovalbumin) Serva Electrophoresis 
Albumin Fraction V (BSA) Roth 
Ammonium persulfate Sigma-Aldrich 
Calciumchlorid (CaCl2) Roth 
CFSE Proliferation Dye eBioscience 
ColorPlus Prestained Protein Ladder New England BioLabs 
Complete EDTA-free protease inhibitor cocktail tablets Roche 
Dephostatin Santa Cruz 
Dulbecco’s Modified Eagle’s Medium (DMEM) Pan Biotech 
DyNAmo ColorFlash SYBR Green qPCR Kit Thermo Scientific 
Ethylenediamintetraacetic acid (EDTA) Roth 
Fetal Bovine Serum PAA Clone PAA 
Fetal Bovine Serum Standard Quality PAA 
Ficoll-Paque™ Premium 1.084 GE Healthcare 
Glycin Pufferan® Roth 
Hoechst 33258 Invitrogen 
Iscove’s Modified Dulbecco’s Medium (IMDM) Pan Biotech 
L-Glutamine (200 mM) PAA 
Lipopolysaccharides from Escherichia coli Sigma-Aldrich 
Methyl-3,4-dephostatin Sigma-Aldrich 
MHCI Peptid OVA (257-264) AnaSpec Inc. 
MHCII Peptid OVA (323-339) AnaSpec Inc. 
Mouse IFN-γ recombinant protein (ELISA Standard) eBioscience 
Mouse IL-2 recombinant protein (ELISA Standard) eBioscience 
Mouse serum Pan Biotech 
Natriumazid Roth 
Natriumchlorid Roth 
NeutrAvidin™ Horseradish Peroxidase Conjugate Thermo Scientific 
Nonfat dried milk powder Appli Chem 
OneComp eBeads eBioscience 
OPTI-MEM® I Gibco 
Ovalbumin (OVA)-Alexa Fluor® 647 conjugate Invitrogen 
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PBS Dulbecco w/o Ca2+ w/o Mg2+ Biochrom 
PD-10 Desaltin Columns, Sephadex G-25 Medium GE Healthcare 
Penicillin/Streptomycin (10,000 units/mL/ 10 mg/mL) Pan Biotech 
phosphorylated biotin-conjugated TATEGQYQPY peptid PSL 
PhosStop phosphatase inhibitor cocktail tablets Roche 
Pierce® BCA Protein Assay Kit Thermo Scientific 
Pierce® Chromatography Cartridges Protein G Thermo Scientific 
Pierce® ECL Western Blotting Substrate Thermo Scientific 
Protein A/G Plus-Agarose Santa Cruz 
PTP CD45 Inhibitor SF1670 Calbiochem 
Restore™ PLUS Western Blot Stripping Buffer Thermo Scientific 
RNeasy® Mini Kit Qiagen 
Roswell Park Memorial Institute 1640 (RPMI 1640) Pan Biotech 
Roti®-Stock 20% SDS Roth 
Sodium Pyruvate (100 mM) Pan Biotech 
Streptavidin Agarose Merck Millipore 
SuperScript® II Reverse Transcriptase Invitrogen 
SuperSignal® West Pico Chemiluminescent Substrate Thermo Scientific 
TMB One  Kementec 
Transferrin-Alexa Fluor® 647 conjugate Invitrogen 
Tris Pufferan® Roth 
β-Mercaptoethanol Roth 
 
4.1.5. Buffers and solutions 
Common buffer 
FACS buffer 
0.1% (w/v) BSA, 0.1% (w/v) NaN3 in 1x PBS; stored at 4 °C 
2 mM EDTA 
0.5 M EDTA diluted 1:250 in 1x PBS; stored at 4 °C 
2x BBS buffer 
50 mM BES, 280 mM NaCl, 1.425 mM Na2HPO4 in H2O; adjusted to pH 7.05; sterile 
filtered; stored at 4 °C 
0.3% BSA 
0.3% (w/v) BSA in 1x PBS; stored at 4 °C 
0.5 M EDTA 
500 mM EDTA in H2O; adjusted with NaOH to pH 8; stored at 4 °C 
 
Media 
BM(GM-CSF) culture medium 
IMDM, 10% FCS Clone, 100 units/mL Penicillin, 0.1 mg/mL Streptomycin, 50 mM β-
Mercaptoethanol, 2.5% J558 supernatant 
BM(GM-CSF) survey medium 
IMDM, 10% FCS Clone, 100 units/mL Penicillin, 0.1 mg/mL Streptomycin, 50 mM β-
Mercaptoethanol 
T cell medium 
RPMI 1640, 10% FCS Standard, 100 units/mL Penicillin, 0.1 mg/mL Streptomycin, 50 
mM β-Mercaptoethanol 
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HEK cell medium 
DMEM, 10% FCS Standard, 100 units/mL Penicillin, 0.1 mg/mL Streptomycin, 1mM 
Sodium Pyruvate 
YBM medium 
IMDM, 5% FCS Standard, 2 mM L-glutamine, 100 units/mL Penicillin, 0.1 mg/mL 
Streptomycin 
 
Buffers for FcMR generation 
0.02% NaN3 
0.02% (w/v) NaN3 in H2O; stored at 4 °C 
Binding buffer for Protein G column 
50 mM sodium acetate in H2O; adjusted to pH 5.0; stored at 4 °C 
Elution buffer for Protein G column 
0.1 M glycine in H2O; adjusted to pH 2.5; stored at 4 °C 
Neutralisation buffer for Protein G column 
1 M Tris in H2O; adjusted to pH 7.5; stored at 4 °C 
Protein G column storage buffer 
0.05% NaN3 (w/v) in H2O; stored at 4 °C 
 
SDS-PAGE and Western Blot buffer 
10% APS 
1 g APS in 10 mL H20; stored at -20 °C 
1x TBS 
50 mM Tris, 150 mM NaCl in H2O; adjusted to pH 7.6; stored at RT 
1x SDS-Running buffer 
150 mM Glycin, 25 mM Tris, 0.1% SDS (v/v) in H2O; stored at RT 
1x Towbin buffer 
25 mM Tris, 192 mM Glycin in H2O; stored at RT 
4x SDS Protein Sample buffer/Laemmli buffer 
40% Glycerol (v/v), 240 mM Tris/HCl (pH 6.8), 8% SDS (v/v), 0.04% Bromphenolblue 
(v/v) in H2O, if necessary 5% β-Mercaptoethanol (v/v); stored at RT 
Triethanolamine-buffered (TEA) lysis buffer 
10 mM Triethanolamine (pH 8.2), 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% Triton 
(v/v) in H2O; stored at 4 °C 
fresh added: 1x EDTA-free protease inhibitor cocktail 
PBST 
0.1% TWEEN®20 (v/v) in 1x PBS; stored at RT 
TBST 
0.1% TWEEN®20 (v/v) in 1x H2O; stored at RT 
 
 
ELISA buffer 
ABTS buffer 
0.1 M Citric acid in H2O; adjusted to pH 4.35; stored at 4 °C 
ELISA Coating buffer 
0.1 M NaHCO3 in H2O; adjusted to pH 8.2; stored at 4 °C 
ELISA Wash Buffer 
0.05% TWEEN®20 (v/v) in 1x PBS; stored at RT 
ELISA Blocking Buffer 
1% BSA (w/v) in 1x PBS; stored at 4 °C 
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ABTS substrate solution 
1 mg/mL ABTS, 15 µL H2O2 in 10 mL ABTS buffer; prepared freshly 
 
Phosphatase assay buffer 
Phosphatase assay lysis buffer 
20 mM HEPES (pH 7.2), 2 mM EDTA, 1% Nonident P-40 (v/v), 10% Glycerol (v/v) in 
H2O; stored at 4 °C 
fresh added: 1x EDTA-free protease inhibitor cocktail, 2 mM Dithiothreitol (DTT) 
Phosphatase assay Buffer 
20 mM HEPES (pH 7.2), 2 mM EDTA in H2O; stored at 4 °C 
fresh added: 2 mM Dithiothreitol (DTT) 
100 mM HEPES 
100 mM HEPES in H2O; stored at 4 °C 
4.1.6. Antibodies 
Primary antibodies for flow cytometry 
Antigen Clone Species Company Conjugate Conc. 
(ng/mL) 
anti-CD206 MR5D3 rat AbD Serotec Alexa Fluor® 647 125  
anti-CD11b M1/70 rat eBioscience FITC 1250  
anti-CD11c N418 rat eBisocience eFluor® 450 500  
anti-F4/80 BM8 rat eBioscience eFluor® 660 500  
anti-CD45 30-F11 rat BioLegend PerCP/Cy5.5 500  
anti-
CD45R/B220 
RA3-6B2 rat BioLegend APC/Cy7 500 
anti-CD45RB 16A rat Santa Cruz FITC 500  
anti-CD45RC C455.1F rat Santa Cruz PE 250  
anti-CD40 3/23 rat Abd Serotec PE 250 
anti-CD4 GK1.5 rat BioLegend PerCP/Cy5.5 500  
anti-CD8 53-6.7 rat eBioscience PerCP/Cy5.5 500  
anti-CD80 16-10A1 rat eBioscience PE 500  
anti-CD86 PO3 rat Abd Serotec Alexa Fluor® 488 250  
anti-MHCI AF6-120.1 mouse BioLegend Alexa Fluor® 647 500  
anti-MHCII M5/114.15.2 rat eBioscience PerCP/Cy5.5 500  
anti-B7H1 MIH5 rat eBioscience PE 500  
anti-B7H2 HK5.3 rat BioLegend PE 500  
 
Primary antibodies for complexation, phosphatase assay, IP and Western Blot 
Antigen Clone Species Company Conjugate Conc. 
(ng/mL) 
anti-GAPDH 6C5 mouse Millipore purified 100  
anti-Vinculin - rabbit Sigma purified 1000  
anti-CD206 MR5D3 rat AbD Serotec purified 1000  
anti-CD206 MR5D3 rat AbD Serotec Biotin 100  
anti-human CD206 7-450 mouse Acris purified 500  
anti-human CD206 15-2 mouse BioLegend Biotin 100  
anti-human IgG - rabbit Santa Cruz HRP 4000  
anti-CD45 30-F11 rat BioLegend Biotin 500  
anti-CD45 30-F11 rat BioLegend purified 500  
anti-CD45RA 14.8 rat Santa Cruz purified 1000  
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anti-CD45RB C363-16A rat Abd Serotec purified 500  
anti-CD45RC C455.1F rat Santa Cruz purified 500  
anti-
Phosphotyrosine 
4G10 mouse Millipore purified 200  
anti-Calnexin - rabbit Abcam purified 1000  
 
Secondary antibodies 
Antigen Species Company Conjugate Conc. 
(ng/mL) 
anti-rat goat Jackson Immuno HRP 160  
anti-rabbit goat Santa Cruz HRP 80  
anti-mouse goat Dianova HRP - 
 
ELISA antibodies (used concentration 0.5 µg/mL) 
Antigen Clone Species Company Conjugate 
anti-IFN-γ AN-18 rat eBioscience purified 
anti-IFN-γ RA-6A2 rat eBioscience Biotin 
anti-IL-2 JES6-1A12 rat eBioscience purified 
anti-IL-2 JES6-5H4 rat eBioscience Biotin 
anti-IL-6 MP5-20F3 rat eBioscience purified 
anti-IL-6 MP5-32C11 rat eBioscience Biotin 
anti-IL-10 JES5-16E3 rat eBioscience purified 
anti-IL-10 JES5-2A5 rat eBioscience Biotin 
anti-IL-12 p35/p70 C18.2 rat eBioscience purified 
anti-IL-12/IL-23 p40 C17.8 rat eBioscience Biotin 
anti-IL-4 11B11 rat eBioscience purified 
anti-IL-4 BVD6-24G2 rat eBioscience Biotin 
 
Cell stimulation antibodies 
Antigen Clone Species Company Conjugate Conc. 
anti-CD3ε 17A2 rat eBioscience purified 5 µg/mL 
4.1.7. Primers 
All primers were purchased from Life technologies 
 
cDNA production 
Primer Sequence 
OligodT TTTTTTTTTTTTTTTTT 
 
RT-PCR 
Primer Sequence 
HPRT_for TCCCAGCGTCGTGATTAGCGATGA 
HPRT_rev AATGTGATGGCCTCCCATCTCCTTCATGACAT 
PPIA_for GCGTCTCCTTCGAGCTGTT 
PPIA_rev RAAGTCACCACCCTGGCA 
SOCS3_for ATTTCGCTTCGGGACTAGC 
SOCS3_rev AACTTGCTGTGGGTGACCAT 
STAT1_for AAATGTGAAGGATCAAGTCATGTG 
STAT1_rev CATCTTGTAATTCTTCTAGGGTCTTGA 
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STAT3_for GTTCCTGGCACCTTGGATT 
STAT3_rev CAACGTGGCATGTGACTCTT 
STAT6_for CCTTTGAGGAGAGCCTAGCA 
STAT6_rev CTGCTGCAGCTGGGAATAA 
TBP_for CCAATGACTCCTATGACCCCTA 
TBP_rev CAGCCAAGATTCACGGTAGAT 
4.1.8. Equipment 
Device Company 
BioLogic LP System (peristaltic pump) Bio-Rad Laboratories 
ChemiDocTM MP System Bio-Rad Laboratories 
Flow Cytometer LSR II  BD Biosciences 
Infinite F200PRO plate reader Tecan 
iQ™5-Real-time PCR Detection System Bio-Rad Laboratories 
Mini-PROTEAN® Tetra and Mini Trans-Blot® Cell System Bio-Rad Laboratories  
NanoDrop 2000 spectrophotometer Thermo Scientific 
QuadroMACSTM Separation Unit and MACS Multi Stand Miltenyi Biotec 
Thermo MultiscanEX Plate reader Thermo Scientific 
4.1.9. Software 
Software Company 
Adobe Acrobat Pro Version 10.1.14 Adobe System 
Adobe Illustrator CS5 Version 15.0.0 Adobe System 
BD FACSDivaTM BD Biosciences 
BioLogicTM LP Data ViewTM  Bio-Rad Laboratories 
FlowJo Version 9.6.4 FlowJo Enterprise 
GraphPad Prism 5 for Mac OS X Version 5.0c GraphPad Software 
Image LabTM Version 5.1 Bio-Rad Laboratories 
iQ5 Optical System Software Bio-Rad Laboratories 
Microsoft® Office for Mac 2011 Microsoft 
NanoDrop 2000/2000c Thermo Scientific 
TECAN plate reader software i-control 1.10 Tecan 
4.2. Methods  
4.2.1. Generation and stimulation of BM(GM-CSF) cells 
4.2.1.1  Standard ce l l  cul ture condit ions 
Cells were cultured under standard cell culture conditions at 37 °C at levels of 5% CO2 
and a relative humidity of 90%. If not mentioned otherwise, cells were detached by 
incubation with 2 mM EDTA in PBS for 5 min at 37 °C followed by gently pipetting. 
BM(GM-GSF) and HEK293 T cells were centrifuged 5 min at 300 rcf whereas 
splenocytes were centrifuged 10 min at 450 rcf. 
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4.2.1.2  Product ion o f  GM-CSF-containing ce l l  supernatant  
GM-CSF for BM(GM-CSF) cell differentiation was produced by J558L cells. This mouse 
BALB/c B myeloma cell line is able to secrete GM-CSF into its supernatant. Cells were 
thawed, expanded and then, 106 cells were plated in 30 mL survey medium on a 15 cm 
cell culture dish. After 8-10 days of incubation, supernatant was centrifuged 5 min at 300 
rcf and sterile filtered using bottle-top filter from Corning. GM-CSF-containing cell 
supernatant was aliquoted and stored at -20 °C. 
4.2.1.3  Different iat ion o f  BM(GM-CSF) ce l l s  
A mouse was euthanized, killed by cervical dislocation and tibiae and femurs were taken 
out. Under sterile conditions and in 1x PBS, bones were opened on both ends and bone 
marrow was flushed out with PBS and a 26G x 1’’ gauge needle. Cells were separated by 
pipetting, filtered through a 40 µm nylon mesh and centrifuged for 5 min at 300 rcf. 
Supernatant was discarded and cells were resuspended in 45 mL BM(GM-CSF) culture 
medium comprising 2.5% GM-CSF-containing cell supernatant. 15 mL cell suspension 
per 10 cm petri dish was plated and incubated for 3-4 days at 37 °C. Then, supernatant 
with swimming cells of 3 plates was collected in a 50 mL reaction tube, adherent cells 
were detached with 2 mM EDTA (see. 4.2.1.1) and combined with the supernatant. Cells 
were centrifuged for 5 min at 300 rcf, supernatant was discarded and cells were 
resuspended in double volume (90 mL) fresh culture medium. Again, 15 mL cell solution 
were plated per 10 cm petri dish and incubated 3-4 days. BM(GM-CSF) cells were used 
on day 7 or 8. 
4.2.1.4  FcMR and sMR st imulat ion 
For stimulation with FcMR or sMR, MR-KO BM(GM-CSF) cells were plated on day 7 at 
a concentration of 106 cells/mL in sMR-containing supernatant (production see 4.2.3) or 
survey medium supplemented with complexed MR proteins (complexation see 4.2.2.5). 
Cells were incubated O/N at 37 °C. 
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4.2.2. Generation of recombinant MR protein 
4.2.2.1  Recombinant MR vec tors  
The chimeric MR construct consists of the CR domain, FN domain and CTLD 1-2 of 
the MR fused to a human Fc part of IgG1. It was cloned in the backbone of plgplus 
vector that has an ampicillin and kanamycin resistance as well as an IL-2 signal sequence 
fot he secretion of the chimeric protein. (Figure 12) The plasmid were cloned and 
kindly provided by Luisa Martinez-Pomares 60. As isotype control the pFuse-hIgG1-Fc2 
vector from InvivoGen was used. The plasmid contains an IL-2 signal sequence for 
secretion and the human IgG1 Fc part equal to plgplus-CR-FN-CTLD1-2 (Figure 11).  
 
Figure 11: Vector map of pFuse-hIgG1-Fc2. The vector was purchased from InvivoGen and served as 
isotype control. 
 
 
Figure 12: Vector map of plgplus-CR-FN-CTLD1-2. The vector was cloned and provided by Luisa 
Martinez-Pomares 60. The plasmid encodes the chimeric protein FcMR containing cysteine-rich (CR), 
fibronectin (FN) type II, and C-type lectin-like domains (CTLD) 1-2 of the MR fused to a human IgG1 Fc 
part.  
IL-2 SS 545..632
hEF1-HTLV_promotor 1..544
SV40_promotor 1349..1574
CMV_enhancer 3276..2858
Zeocin 2366..1992
pFuse-hIgG1-Fc2
4194 bp
hIgG1 Fc region 654..1334
Fibronectin Type II domain 682..840
IL-2 SS 214..267
hIgG1 Fc2 1858..2556
NeoR 3697..4491
AmpR 6069..6929
CMV Promoter 7295..7927
pIgplus-CR-FN-CTLD1-2
7952 bp
Cystein-rich domain 268..681
C-type lectin-like domains (CTLD) 1-2 841..1812
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4.2.2.2  Transfec t ion o f  HEK293T ce l l s  
3*106 HEK293T cells were plated on a T75 cell culture flask in 10 mL HEK cell medium 
one day prior transfection. 10 µg DNA per T75 cell culture flask were mixed with 2.5 
mM CaCl2 and water. This mixture was added to an equal amount of 2x BBS buffer 
during constant airflow. After 5 min incubation, the transfection preparation was 
distributed over the cells. On the following day, medium was changed to 20 mL OPTI-
MEM. Transfected cells were cultured 4-5 days at 37 °C and 5% CO2. 
4.2.2.3  Prote in puri f i cat ion via Prote in G co lumn 
Recombinant MR constructs were purified from transfected HEK cells by affinity 
chromatography using a Protein G column from Pierce and BioLogic LP system from 
Bio-Rad. Procedure was done according to the manufacturer’s instructions. Briefly, cell 
supernatant was centrifuged 5 min at 300 rcf to remove cell debris. Supernatant was 
filtered with sterile 0.45 µm cellulose acetate membrane syringe and then mixed in a ratio 
1:2 with binding buffer. Column was equilibrated with 10 mL binding buffer with a flow 
rate of 1.5 mL/min. Sample was run over the column with a constant flow rate of 1 
mL/min. Afterwards, column was washed with 10 mL binding buffer and protein was 
eluted with elution buffer. For both the flow rate was enhanced to 1.5 mL/min. Eluated 
fraction were mixed with neutralization buffer in a ratio of 1:9. Finally, column was 
washed with 5 mL storage buffer for repeated application. Protein concentration of 
eluted fractions was measured at 280 nm with NanoDrop. 
4.2.2.4  Prote in concentrat ion via spin co lumn 
Eluted fractions containing protein were combined. Buffer exchange as well as 
concentration was done by centrifugation at 3200 rcf using a VivaSpin column with a 
cut-off 30k. Protein concentration of concentrated fraction was measured at 280 nm with 
NanoDrop. Recombinant proteins were enriched with 1x protease inhibitor cocktail mix 
and 0.02% NaN2 for long time storage. 
4.2.2.5  Complexation o f  MR prote in 
10 µg MR protein (final concentration; normally 10 µg MR protein per 106 cells or per 
mL medium were used) was mixed with 1x protease inhibitor cocktail mix, 1:100 anti-
human-HRP antibody and 0.3% BSA in PBS in a total volume not less than 100 µL. The 
complexation took place 1 h at RT. 
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4.2.3. Generation of soluble mannose receptor (sMR)-containing cell 
supernatant 
Wt and MR-/- BM (GM-CSF) cells were plated on day 7 at a concentration of 2*106 
cell/mL survey medium on a 10 cm cell culture plate. After 5-7 days incubation at 37 °C 
and 5% CO2, cell supernatant was centrifuged at 300 rcf for 5 min. Supernatant was 
stored at 4 °C. Quality of sMR was analyzed by SDS-PAGE and western blot (see 4.2.4). 
4.2.4. Sodium dodecyl sulfate polyacrylamide gel electrophorese (SDS-
PAGE) and Western Blot 
4.2.4.1  Cell  lys i s  
Cells were plated and incubated differently for the individual experiments. 
After incubation, BM(GM-CSF) cells were scraped off, transferred to a reaction tube and 
centrifuged 5 min at 300 rcf. Supernatant was discarded and cell pellet was lysed in 
Triethanolamine-buffered (TEA) lysis buffer supplemented with protease and 
phosphatase inhibitor mix. Lysis was performed on ice for 5-30 min. Lysate was 
centrifuged 5 min at full speed to remove cell debris. Supernatant was transferred to a 
new tube and stored at -20 °C until further analysis. 
4.2.4.2  SDS-PAGE 
Separation of proteins was done using the MiniProtean® Tetra cell system from Bio-Rad. 
Handling of equipment was according to the manufacturer’s instructions. Percentage of 
resolving gel was geared to the separation range of analyzed proteins. Percentage of the 
stacking gel was 5%. SDS-PAGE was performed at 30 mA const., 120 V and 100 W in 
1x SDS running buffer. 
4.2.4.3  Western Blot  
To analyze proteins, SDS polyacrylamide gel with separated proteins was transferred on a 
nitrocellulose membrane using the Mini Trans-Blot® wet transfer cell system from Bio-
Rad. Assembling of the blot chamber was done according to the manufacturer’s 
instructions. Wet blot transfer was carried out 1 h at 350 mA const., 100 V and 300 W in 
1x Towbin buffer. 
Next, membrane was blocked with 5% milk powder or 5% BSA in TBST or PBST for 1 
h at RT. In most cases, membrane was incubated in primary antibody diluted in blocking 
solution 1 h at RT followed by three washing steps of 5 min each with TBST or PBST. 
Then, secondary antibody incubation was performed in TBST or PBST for 1 h at RT 
Material and Methods 
 
 30 
followed by three washing steps of 5 min each with TBST or PBST. The staining 
procedure was performed under rocking conditions. Detection of the protein of interest 
was done by chemiluminescence with SuperSignal® West Pico Chemiluminescent 
substrate from Pierce® and ChemiDoc™ MP Imaging System from Bio-Rad. 
4.2.5. Immunprecipitation of CD45  
4.2.5.1  Preparat ion and pre- c l earance o f  prote in lysates  
For generation of CD45-containing cell lysate see 4.2.4.1. First, unspecific binding of 
samples was removed by pre-clearance. 10 µL protein A/G beads were washed twice 
with PBS by centrifugation at 6800 rcf for 30 sec. Beads were incubated with cell lysates 
for 1 h at 4 °C on a rotation wheel. Subsequently, beads were centrifuged (6800 rcf 30 
sec) and supernatant was transferred in a new tube. 
4.2.5.2  Pull -down 
Cell lysates were incubated with 0.5 µg anti-CD45 (clone 30-F11) antibody for 1 h at 4 
°C on a rotation wheel. In the meantime, 20 µL protein A/G beads per sample were 
washed twice with PBS. Samples were loaded to the beads and incubated for 1 h at 4 °C 
on a rotation wheel. Beads were spun down (6800 rcf for 30 sec) and supernatant were 
discarded. Beads were washed twice with lysis buffer or PBS in case of cell lysate or cell 
supernatant, respectively. 1x Laemmli buffer (LB) w/o β-mercaptoethanol was added to 
the beads and samples were boiled 5 min at 97 °C. Supernatant was loaded on SDS-
PAGE. 
4.2.5.3  Western blot  analys is  
Immunoprecipitated proteins were analyzed by SDS-PAGE (see 4.2.4.2) and western 
blot (see 4.2.4.3) 
Blocking was done with 5% BSA in TBST and all washing steps were performed with 
TBST. Rat anti-CD45 biotin-labeled (clone 30-F11) antibody was used 1:1000 followed 
by detection with NeutrAvidin horseradish peroxidase (NaPOX) 1:5000. 
4.2.6. CD45 phosphatase assay 
For stimulation with FcMR, 3.5*106 MR-/- BM(GM-CSF) cells were plated in a 6-well 
plate in survey medium. After 1 h, complexed MR constructs (for complexation see 
4.2.2.5) (10 µg/106 cells) were added to the medium and cells were incubated for 1 h at 
37 °C.  
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For stimulation with sMR, 5*106 MR-/- BM(GM-CSF) cells were plated in a 6-well plate 
in supernatant of wt or MR-/- BM(GM-CSF) cells (for generation see 4.2.3) and incubated 
for 1 h at 37 °C. 
After MR incubation, supernatant of cells was discard and cells were lysed in 600 µL 
phosphatase assay lysis buffer for 15-30 min on ice. After this point, samples were 
handled separately depending on phosphatase activity detection by 4-NPP substrate or 
phospho-TATEGQYQPY peptid. 
4-NPP substrate: 10 µL protein A/G beads per sample were washed twice with 1x PBS 
(6800 rcf for 30 sec). Cells were scraped off, added to the prepared beads and incubated 
for 1 h at 4 °C on a rotation wheel. Beads were centrifuged for 30 sec at 680 rcf and 
supernatant was split into three equal fractions. anti-CD45 antibody was added and 
samples were incubated for 1 h at 4 °C with rotation. In the meantime, 20 µL protein 
A/G beads per sample were washed twice with 1x PBS (6800 rcf for 30 sec). Antibody-
coupled lysates were added to the prepared beads and incubated for 1 h at 4 °C on a 
rotation wheel. Beads were washed twice with 100 mM HEPES solution. Before second 
washing step, each sample was split in two fractions. 70 µL CD45 substrate (4-NPP)-
containing phosphatase assay buffer supplemented with or without 2 µM CD45 inhibitor 
SF1670 was added to the beads. Samples were incubated O/N at 37 °C and 500 1/min 
in the dark. Beads were centrifuged for 1 min at 6800 rcf and supernatant were 
transferred to an ELISA plate. Analysis of substrate conversion was measured by 
colorimetry at 405 nm. 
phospho-TATEGQYQPY peptid: Lysates were centrifuged for 5 min at full speed to 
remove cell debris. Supernatant was split into three equal fractions and 1.25 µg anti-
CD45 antibody per sample was added. Samples were incubated for 1 h at 4 °C with 
rotation. In the meantime, 20 µL protein A/G beads per sample were washed twice with 
1x PBS (6800 rcf for 30 sec). Antibody-coupled lysates were added to the prepared beads 
and incubated for 1 h at 4 °C on a rotation wheel. Beads were washed twice with 1x PBS. 
70 µL phosphatase assay buffer supplemented with 0.25 µg/mL phospho-
TATEGQYQPY peptid was added to the beads. Samples were incubated O/N at 37 °C 
and 500 1/min in the dark. 25 µL streptavidin agarose per sample were washed twice 
with 1x PBS (6800 rcf for 30 sec). O/N-incubated samples were filled up with 500 µl 1x 
PBS and centrifuged for 30 sec at 6800 rcf. 500 µl supernatant were transferred to 
streptavidin agarose and incubated for 1 h at 4 °C with rotation. Agarose beads were 
centrifuged for 30 sec at 6800 rcf and supernatant was discarded. 500 µl 3% BSA in PBS 
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supplemented with 1:10,000 anti-phosphotyrosine antibody (clone 4G10) were added to 
the beads. Samples were incubated for 1 h at 4 °C with rotation. Beads were centrifuged 
for 30 sec at 6800 rcf and supernatant was discarded. 500 µl 3% BSA in PBS 
supplemented with 1:10,000 anti-mouse-HRP antibody were added to the beads. Samples 
were incubated for 30 min at 4 °C with rotation. Beads were washed twice with 1x PBS 
and once with H2O. Dephosphorylation of peptide was analyzed with TMB substrate 
and measured by colorimetry at 450 nm. 
4.2.7. Detection of phosphotyrosine levels 
2*106 MR-/- BM(GM-CSF) cells were plated in a 6-well plate. Next day, cells were washed 
with 1x PBS and stimulated with 10 µg FcMR or 1 mL sMR for 30 min at 37 °C. 
Afterwards, cells were lysed as described in 4.2.4.1. Protein concentration was 
determined by bicinchoninic acid (BCA) assay. 15 µg protein lysate/sample was loaded 
on SDS-PAGE and detected by immunoblotting (see 4.2.4.3). Membranes were blocked 
with 5% BSA in TBST for 1 h at RT.  
Next, membranes were incubated in phosphotyrosine-specific antibody (clone 4G10) 
diluted in blocking solution O/N at 4 °C followed by three washing steps of 5 min with 
TBST, followed by incubation with anti-mouse-HRP antibody in TBST for 1 h at RT. 
After extensive washing, membranes were detected with ECL reagent followed by 
membrane stripping with Restore™ PLUS Western Blot stripping buffer and restaining 
with anti-GAPDH antibody. 
4.2.8. Quantitative Real-time polymerase chain reaction (qRT-PCR) 
3*106 MR-/- BM(GM-CSF) cells were plated in a 6-well plate and stimulated with 10 µg 
complexed FcMR/106 cells for 4 h or 12 h at 37 °C. After incubation, cells were scraped 
off and RNA was isolated using RNeasy® Mini Kit (Qiagen). Subsequently, 500 ng total 
RNA was used to generate cDNA using SuperScript® II Reverse Transcriptase 
(Invitrogen). Afterwards, analysis of gene expression was performed with DyNAmo 
ColorFlash SYBR Green qPCR Kit (Thermo Scientific) on an iQ™5 Real-time Detection 
System (BioRad). All kits were used according to the manufactures instructions. PCR was 
prepared and run with the following mix and program. 
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PCR Mix final 
2x Master Mix 1x 
5 µM Primer Mix 0.5 µM each 
40x Yellow sample buffer 1x 
Template cDNA 1 µl 
H2O up to 15 µl 
 
PCR Programm Time Temperature  
Denaturation 7 min 95 °C  
Denaturation 10 sec 95 °C 
44 cycles Annealing 15 sec 60°C 
Extension 30 sec 72 °C 
Melting curve each  
30 sec 
55-95 °C 
in 0.5 °C steps 
 
 
4.2.9. Flow cytometry analysis of cell surface molecules 
BM(GM-CSF) cells were stimulated on day 7 with FcMR or sMR (see 4.2.1.4). After 24 
h, cells were scraped off and transferred to FACS tubes. 2 mL FACS buffer were added 
per tube and samples were centrifuged for 5 min at 300 rcf. Supernatant were discarded 
and cells were stained with fluorescent-labeled antibodies in a ratio of 1:400 for 20 min at 
4 °C in the dark. Mouse serum was added (final ratio 1:100) to block unspecific antibody 
binding. 
After incubation, cells were washed once with 2 mL FACS buffer by centrifugation for 5 
min at 300 rcf and analyzed by flow cytometry on LSRII. 
4.2.10. Antigen uptake assay 
After stimulation with FcMR or sMR (see 4.2.1.4), 4*105 BM(GM-CSF) cells were plated 
in a 24-well plate and incubated for 45 min. Medium was changed to medium containing 
250 ng/mL ovalbumin-Alexa Fluor® 647 or 5 µg/mL transferrin-Alexa Fluor® 647 and 
incubated for 15, 30, or 60 min at 37 °C. After incubation, cells were scraped off, 
transferred to a FACS tube and washed once with FACS buffer by centrifugation at 300 
rcf for 5 min. Supernatant was discarded and cells were resuspended in 500 µL FACS 
buffer. Antigen uptake was analyzed by flow cytometry on LSR II. 
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4.2.11. T cell function assays 
4.2.11.1  Iso lat ion o f  pr imary splenocytes  
Mice were killed by cervical dislocation. Spleen was taken out and stored in 1x PBS on 
ice. Under sterile conditions and in 1x PBS, spleen was shredded through a 100 µm metal 
mesh with a plunger of a syringe. Cells were further singularized by pipetting and filtered 
through a 40 µm nylon mesh. Cells were counted and used directly for co-culturing (see 
4.2.11.4) or stained with CFSE (see 4.2.11.2). 
4.2.11.2  CFSE-staining o f  splenocytes 
To analyze proliferation of T cells, splenocytes were stained with CFSE. Isolated 
splenocytes (see 4.2.11.1) were centrifuged for 10 min at 450 rcf and resuspended in 10 
mL 1x PBS. Cell solution was mixed 1:2 with 10 mL 2 µM CFSE in PBS (final 
concentration of 1 µM CFSE). Cells were incubated for 15 min at 37 °C in the dark. 
Staining was stopped through addition of 20 mL T cell medium. Unbound CFSE was 
removed by washing three times with 10 mL T cell medium by centrifugation for 7 min 
at 450 rcf. Cells were counted and resuspended at a concentration of 106 cells/mL in T 
cell medium. 
4.2.11.3  Ovalbumin (OVA) preparat ion 
As an extracellular antigen for T cell activation OVA was used. OVA was dissolved in 1x 
PBS to a final concentration of 100 mg/mL. After centrifugation for 5 min at full speed 
to remove unsolved OVA, it was purified from small OVA fragments by gel filtration via 
a PD10 column. Final concentration was measured at 280 nm with NanoDrop. OVA 
was always prepared freshly for each experiment. 
4.2.11.4  BM(GM-CSF)/T ce l l  co- cul ture 
FcMR- or sMR-prestimulated BM(GM-CSF) cells (see 4.2.1.4) were plated for IL-2 
secretion and proliferation at a density of 5*104 cells/well in a 96-well plate and for in 
vitro cytotoxicity assay and restimulation at a density of 4*105 cells/well in a 24-well plate. 
Cells were incubated for 1-2 h at 37 °C. For the priming of CD4+ OT-II T cells, medium 
of BM(GM-CSF) wells were changed to medium supplemented with 1 mg/mL OVA and 
cells were incubated 3 h at 37 °C.  
Afterwards, BM(GM-CSF) cells were co-cultured with 105 splenocytes/96-well or 5*105 
splenocytes/24-well at 37 °C for indicated time points. 
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For IL-2 secretion, in vitro cytotoxicity assays, and restimulation, unlabeled DesTCR or 
OT-II splenocytes were used, for proliferation CFSE-labeled splenocytes (see 4.2.11.2) 
were used. All experiments were performed in triplicates. 
4.2.11.5  IL-2 secre t ion 
24 h after co-culturing of BM(GM-CSF) cells with DesTCR or OT-II splenocytes, 
supernatant of cells were centrifuged for 7 min at 450 rcf to remove cells and stored at -
80 °C. Secretion of IL-2 were analyzed by ELISA (see 4.2.12). 
4.2.11.6  Prol i f erat ion assay 
For analysis of proliferation, BM(GM-CSF) cells and CFSE-stained DesTCR or OT-II 
splenocytes were co-cultured 3 days. Next, cells were washed once with 1x FACS buffer 
by centrifugation at 450 rcf for 5 min. Antigen-specific OT-II and DesTCR T cells were 
stained with anti-CD4 (1:400) or anti-CD8 (1:400) antibody, respectively. Staining was 
performed for 20 min at 4 °C. Cells were washed again with 1x FACS buffer by 
centrifugation and analyzed by flow cytometry on LSR II. Washing, staining and analysis 
was performed in 96-well plate format. 
4.2.11.7  T ce l l  puri f i cat ion by densi ty  gradient centr i fugat ion 
For in vitro cytotoxicity assay and restimulation, T cells have to be separated from 
BM(GM-CSF) cells after priming. DesTCR splenocytes were primed 3 days, OT-II 
splenocytes were primed 5 days. Primed cells were isolated by density gradient 
centrifugation. T cells were resuspended by gently pipetting and transferred to a 15 mL 
reaction tube. Triplicates were combined. Cells were centrifuged for 10 min at 450 rcf, 
supernatant was discarded and cells were resuspended in 5 mL T cell medium. Cell 
solution was carefully underlaid with 2 mL Ficoll. Samples were centrifuged for 20 min at 
800 rcf with acceleration of 7 and without brake. Cells were carefully collected from the 
interphase and mixed with 8 mL PBS to dilute remaining Ficoll. Samples were 
centrifuged for 10 min at 450 rcf, supernatant was discarded and cells were resuspended 
in T cell medium. After counting, cells were diluted to a concentration of 4*105 or 
2.5*105 cells/mL for in vitro cytotoxicity assay or restimulation respectively. 
4.2.11.8  In vi tro cy totoxic i ty  assay 
RMA and RMA-S cells were used as target and control cells, respectively. The same 
number of both cell lines was centrifuged for 10 min at 450 rcf and cells were 
resuspended in 1 µM or 0.1 µM CFSE (RMA and RMA-S, respectively). Cells were 
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incubated for 15 min at 37 °C in the dark. CFSE staining was stopped by adding 10 mL 
T cell medium. Cells were washed three times with T cell medium by centrifugation for 
10 min at 450 rcf. Afterwards, cells were counted and mixed together equally to a final 
concentration of 8*104 cells/mL. 100 µL CFSE-stained RMA/RMA-S mix per well was 
plated in a 96-well plated. 100 µL purified, primed DesTCR T cells were added to 
RMA/RMA-S cells in the ration 5:1 and 2:1 (2*105 cells/mL and 8*104 cells/mL, 
respectively) DesTCR/RMA cells. As a control RMA/RMA-S mix without DesTCR T 
cells was analysed. Cells were incubated O/N at 37 °C.  
Next day, killing of RMA cells was analyzed by flow cytometry on LSRII. 10 µg/mL 
Hoechst 33258 (1:100) was added immediately before analysis to stain death cells. 
The percentages of living RMA and RMA-S cells of the co-culturing with (w/) DesTCR 
T cells versus the control without (w/o) DesTCR T cells were used to calculate the 
specific cytotoxicity. The following formula was used. 
 
%  𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 100− 100 ∗ 𝑅𝑀𝐴  𝑐𝑒𝑙𝑙𝑠  (𝑤/)𝑅𝑀𝐴 − 𝑆  𝑐𝑒𝑙𝑙𝑠  (𝑤/)𝑅𝑀𝐴  𝑐𝑒𝑙𝑙𝑠  (𝑤/𝑜)𝑅𝑀𝐴 − 𝑆  𝑐𝑒𝑙𝑙𝑠  (𝑤/𝑜)  
 
4.2.11.9  Rest imulat ion o f  T ce l l s  
To restimulate primed T cells, a 96-well plate was coated with 5 µg/mL anti-CD3 
antibody in 1x PBS for 1 h at 37 °C. Next, 5*104 purified T cells/well were plated on 
CD3-coated 96-well plate. Cells were incubated O/N at 37 °C. Plate was centrifuged for 
5min at 450 rcf and supernatant was used for ELISA to analyze secreted cytokines. 
4.2.12. Enzyme-linked immune sorbent assay (ELISA) 
An ELISA plate was coated for 1 h at 37 °C or O/N at 4 °C with 0.5 µg/mL capture 
antibody (purified) in ELISA coating buffer. Plate was washed three times with ELISA 
washing buffer and blocked with ELISA blocking solution for 30 min at RT. Afterwards, 
plate was washed again three times and 50 µL of samples or protein standard was loaded. 
Standard range covered 125 ng/mL – 120 pg/mL for IFN-γ and 80 ng/mL – 8 pg/mL 
for IL-2 in a dilution ratio of 1:2. 50 µL T cell medium was loaded as blank. Plate was 
incubated for 1 h at 37 °C or O/N at 4 °C. After incubation, plate was washed again and 
incubated with 0.5 µg/mL detection antibody (biotin-labeled) in blocking solution for 1 h 
at 37 °C or O/N at 4 °C. Plate was washed again and incubated for 30 min at RT with 1 
µg/mL NeutrAvidin-peroxidase (NA-POX) in 1x PBS. ABTS solution was prepared and 
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after last washing step, 50 µL ABTS solution per well was loaded. Analysis of substrate 
conversion was measured by colorimetry at 405 nm. 
4.2.13. Detection of sMR in serum samples of mice and human 
Serum samples of wt mice fed a low-fat died (LFD) or a high-fat died (HFD) as well as 
of lean and obese humans were kindly provided by Bruno Guigas of the Leiden 
University Medical Center.  
The relative amount of sMR in the serum was determined by pull-down and western blot 
analysis. 
15 µL mouse serum or 200 µL human serum was pre-cleared with 10 µL protein A/G 
beads for 1-1.5 h at 4 °C under rotating conditions. 1 µg anti-mouse or anti-human MR 
antibody per sample was coupled to 10-20 µL protein A/G beads. All samples were 
centrifuged for 30 sec at 4 °C at 6800 rcf and supernatant of pre-cleared beads was added 
to antibody-coupled beads. Samples were incubated for 1.5-2 h at 4 °C under rotating 
conditions, centrifuged and the supernatant was discarded. Beads were washed two times 
with 200 µL TEA lysis buffer. Samples were centrifuged, the supernatant discarded and 
beads were boiled for 5 min at 99 °C with 15-20 µL 1x Laemmli buffer. Subsequently, 
supernatant was used for SDS-PAGE and western blot analysis (see 4.2.4.2 and 4.2.4.3). 
For the detection of human samples, membranes were blocked in 5% BSA in TBST and 
stained with anti-human CD206-Biotin (1:5000) in blocking solution and in NA-POX 
(1:8000) in TBST. For detection of murine samples see 4.2.4.3. 
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5. Results 
5.1. CD45 in BM(GM-CSF)  
5.1.1. Characterization of GM-CSF generated BM cells 
For decades, bone marrow (BM) cells were used to study the role of APC in vitro, 
especially DCs and MΦs, because a huge number of cells can be prepared from BM 
progenitor cells. In addition, these cells bear many features of primary APCs. They 
express costimulatory molecules, initiate antigen uptake and processing to activate T cell-
mediated immunity, and undergo maturation in response to microbial stimuli 8,89. The 
continuous supply of different cytokines influences the development of generated cells. 
Traditionally, DCs and MΦs were differentiated predominantly by GM-CSF and M-CSF, 
respectively. To date, it is known that a heterogeneous population of DCs, MΦs, and 
granulocytes are generated in GM-CSF cultures 90–92. Due to problem of controversial 
discussed terms (regarding DCs and MΦs) the cells in the presented experiments were 
defined based on the origin and the linked activation standards recommended by Murray 
et al. as BM(GM-CSF) cells 93. 
First, the BM(GM-CSF) cells derived from MR knockout mice were characterized by 
their expression of different surface molecules CD11b, CD11c, and F4/80 of DCs and 
MΦs. BM(GM-CSF) cells were stained with fluorescent-labeled antibodies against the 
extracellular surface markers, and analyzed by flow cytometry (Figure 13).  
 
Figure 13: GM-CSF treatment of bone marrow cells led to a heterogeneous cell population of 
APCs. MR-/- BM(GM-CSF) cells were stained with fluorescent-labeled antibodies against CD11b, 
CD11c, and F4/80 on day 7 of generation. Expression of surface markers was analyzed by flow 
cytometry. Unstained cells were used as control (filled gray). Representative graphs from 1 out of 3 
independent experiments are shown. 
unstained
stained
F4/80CD11cCD11b
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CD11b and F4/80 were expressed by all BM(GM-CSF) cells as it can be seen by the shift 
compared to unstained cells (left and right panel). A subpopulation of BM(GM-CSF) 
cells did also express CD11c (middle panel). 
5.1.2. CD45R0 was expressed by BM(GM-CSF) cells 
CD45 is expressed on the cell surface of all leukocytes. Based on cell type and activation 
state different isoforms are expressed 94. Therefore, the CD45 isoforms on BM(GM-
CSF) cells were analyzed by western blot and flow cytometry in comparison to spleen 
cells. Spleen cells are a mixture of mostly B and T cells. According to the literature, B 
cells express the largest CD45 isoform (comprising all three alternatively spliced exons) 
termed CD45RABC. Primary naïve T cells express CD45RB whereas activated T cells 
express CD45R0 94. 
To investigate the isoform expression on BM(GM-CSF) cells, antibodies specific to 
single isoforms (CD45RA, CD45RB, or CD45RC) as well as an antibody recognizing all 
isoforms (panCD45) were used. Lysates of BM(GM-CSF) and spleen cells were analyzed 
by western blotting via staining with CD45 specific antibodies (Figure 14).  
 
Figure 14 Alternatively spliced exons of CD45 could not be detected on BM(GM-CSF) cells. (A) 
MR-/- BM(GM-CSF) and (B) MR-/- spleen cells were lysed, separated by SDS-PAGE, and analyzed by 
western blot using CD45 isoform-specific antibodies against panCD45, CD45RA, CD45RB, and 
CD45RC. Calnexin was used to check for equal loading. Representative blots from 1 out of 3 independent 
experiments are shown. 
In cell lysates of BM(GM-CSF) cells two bands around 175 kDa appeared if stained with 
panCD45 antibody that recognize all CD45 isoforms (Figure 14A). No protein was 
detected with isoform-specific antibodies (CD45RA, -RB, -RC) recognizing alternatively 
sliced exons of CD45. In spleen cells all isoform-specific antibodies as well as the 
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panCD45 antibody detected proteins higher than 175 kDa according to the literature 94 
(Figure 14B).  Because the isoform-specific antibodies did not detect CD45 in BM(GM-
CSF) cell lysates this suggest that BM(GM-CSF) cells express CD45R0. 
 
To confirm the data, the surface of BM(GM-CSF) and spleen cells were stained with 
fluorescent-labeled CD45 antibodies and analyzed by flow cytometry (Figure 15).  
 
Figure 15: BM(GM-CSF) cells expressed CD45R0. Flow cytometry analysis of (A) MR-/- BM(GM-CSF) 
and (B) MR-/- spleen cells. Cells of day 7 were stained with fluorescent-labeled CD45 isoform-specific 
antibodies. Representative dot blots from 1 out of 3 independent experiments are shown. 
Whereas in subpopulations of spleen cells all isoforms of CD45 were detected (Figure 
15B) only the panCD45 antibody bound on BM(GM-CSF) cells (Figure 15A).  
According to the western blot analysis, this indicates that BM(GM-CSF) cells 
predominantly express the CD45R0 isoform (missing all three alternatively spliced 
exons).  
5.1.3. MR interacted with CD45 on BM(GM-CSF) cells 
An interaction of the cysteine-rich region of the MR with CD45 was already described by 
Martinez-Pomares in 1999 53. To date, the isoforms of CD45 can bind the MR are still 
not defined. To investigate whether the MR could also bind CD45R0 expressed on 
BM(GM-CSF) cells, a recombinant construct of the MR (FcMR) was used. FcMR 
comprised the cysteine-rich, fibronectin type II, and C-type lectin 1-2 domains of the MR 
fused to a human IgG1 Fc part that allowed purification by affinity chromatography, 
complexation of chimeric protein, and detection by an anti-human antibody. 
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CD45 of MR-/- BM(GM-CSF) cells was immunoprecipitated and analyzed by SDS-
PAGE and western blotting. Protein interaction was detected by far-western blotting 
using complexed FcMR. As a control immunoprecipitation was performed without 
antibody (Figure 16, -). To verify the success of the immunoprecipitation, CD45 was 
also stained on the western blot. 
 
Figure 16: FcMR bound to CD45 of BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were lysed and 
CD45 was immunoprecipitated by anti-CD45 antibody and protein A/G beads. Eluates were separated 
by SDS-PAGE and precipitation of CD45 was stained by anti-CD45 antibody. Binding of FcMR to CD45 
in BM(GM-CSF) cells was detected by far-western using complexed FcMR. Representative blot from 1 
out of 6 independent experiments are shown. 
After immunoprecipitation two CD45-specific bands were detected (Figure 16, left 
panel) that might be due to posttranscriptional modifications of CD45. An interaction of 
FcMR with the upper band of CD45 was traceable (Figure 16, right panel). If no 
antibody was used in the immunoprecipitation neither anti-CD45 nor FcMR detected 
anything that demonstrated the specificity of the precipitation.  
 
In summary, these initial experiments showed that the BM(GM-CSF) cells are a 
heterogeneous population of CD11b+CD11c-F4/80+ and CD11b+CD11c+F4/80+ cells 
expressing CD45. Based on western blot and flow cytometry analysis this CD45 isoform 
represents CD45R0. In addition, FcMR interacts with CD45R0 on BM(GM-CSF) cells 
but only with one of two CD45-specific bands in western blot. 
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5.2. Interaction with the MR influenced activity of BM(GM-CSF) 
cells 
5.2.1. MR reduced CD45 phosphatase activity 
CD45 is a tyrosine phosphatase with a role in TLR-dependent cytokine secretion and 
integrin-mediated adhesion in APCs 30,32–34,36,95. In CD8+ T cells, the phosphatase activity 
of CD45 is inhibited by the interaction with the MR 79. 
Because CD45 in BM(GM-CSF) cells was also bound by the MR (Figure 16) it was 
investigated whether the binding of MR had an influence on phosphatase activity of 
CD45 in BM(GM-CSF) cells.  
MR-/- BM(GM-CSF) cells were incubated with complexed FcMR or isotype control for 1 
h. Subsequently, cells were lysed and CD45 was immunoprecipitated using a CD45-
specific antibody. Afterwards, CD45 phosphatase activity was measured by the 
conversion of the alkaline phosphatase substrate 4-nitrophenyl phosphate (4-NPP) into 
its chromatic dephosphorylated form nitrophenyl in the presence or absence of the 
phosphatase inhibitor SF1670. The turnover of the substrate was analyzed after 18 h by 
colorimetry at 405 nm (Figure 17). As a control, the background of the assay was 
determined by performing the immunoprecipitation without antibody (Ctrl).  
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In all samples containing CD45-specific antibody during immunoprecipitation the 
phosphate substrate 4-NPP was converted and turnover was measured (Figure 17, 
black bars, FcMR and isotype control). When the activity was blocked by a phosphatase 
inhibitor nearly no substrate was converted and values of optical densities (ODs) were 
comparable to the background (Figure 17, white bars), pointing out that measured 
substrate conversion was due to phosphatase activity. The incubation of BM(GM-CSF) 
cells with complexed FcMR clearly reduced the phosphatase activity of CD45 in 
BM(GM-CSF) cell in comparison to the isotype control-treated cells, pointing out that 
the binding of FcMR and CD45 influences CD45 phosphatase activity.  
To validate this result and to exclude dephosphorylation by other (putatively co-
precipitated) phosphatases, the phosphatase activity of CD45 was analyzed by 
dephosphorylation of a biotin-labeled CD45-specific peptide (phospho-
TATEGQpYQPY).  
Immunoprecipitated CD45 was incubated with phosphorylated peptide for 18 h. Then, 
peptide was bound to NeutrAvidin beads and tyrosine-phosphorylation was detected by 
an anti-phosphotyrosine antibody. Conversion of TMB substrate by an HRP-labeled 
secondary antibody was analyzed by colorimetry at 450 nm (Figure 18). 
Figure 17: Phosphatase activity of CD45 measured by 4-NPP substrate was reduced by FcMR. 
CD45 was immunoprecipitated from lysates of FcMR- or isotype control-pretreated MR-/- BM(GM-CSF) 
cells by an anti-CD45 antibody and protein was coupled to protein A/G beads. Phosphatase activity was 
measured by substrate conversion of alkaline phosphatase substrate 4-nitrophenyl phosphate. Assay was 
measured by colorimetry at 405 nm. Activity was blocked by the phosphatase inhibitor SF1670 (Inh; white 
bars). As a control, no antibody was used for pull-down (Ctrl). Data in the graph represent 1 out of 3 
independent experiments ± SEM. P values were calculated by student’s t-test. 
OD [405 nm]
0.0 0.2 0.4 0.6
Isotype control
FcMR
Ctrl
+
-
Inh
Inh
p = 0.055
Results 
 
 44 
 
The detection maximum of the assay was assessed by performing the assay without 
CD45 antibody (Figure 18, -αCD45). Since CD45 was not precipitated without 
antibody, the biotin-labeled CD45-specific peptide could not be dephosphorylated by 
CD45 and anti-phosphotyrosine antibody staining was high. If CD45 was precipitated by 
a CD45-specific antibody, the biotin-labeled peptide should be dephosphorylated 
resulting in reduced phosphotyrosine antibody staining compared to control samples 
without antibody.  
The incubation of BM(GM-CSF) cells with isotype control lead to a clear reduction in 
phosphotyrosine antibody staining compared to control samples without CD45 antibody 
(Figure 18, +αCD45, white bar), pointing out that isotype control did not influence 
CD45 phosphatase activity. CD45 of BM(GM-CSF) cells that were stimulated with 
FcMR showed an reduced CD45 phosphatase activity compared to isotype control-
treated BM(GM-CSF) cells (Figure 18, +αCD45, black bar) depicted by enhanced 
staining with phosphotyrosine antibody. 
 
Taking together, the interaction of FcMR and CD45 on BM(GM-CSF) cells clearly 
reduced CD45 phosphatase activity  in the stimulated cells. 
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Figure 18: Phosphatase activity of CD45 measured by a CD45-specific peptide was reduced by 
FcMR. CD45 was immunoprecipitated from lysates of FcMR- (black) or isotype control- (white) 
pretreated MR-/- BM(GM-CSF) cells by an anti-CD45 antibody and protein was coupled to protein A/G 
beads. Phosphatase activity was measured by dephosphorylation of a CD45-specific peptide 
(TATEGQ-pY-QPQ). Phosphorylation of peptide was detected by an anti-phosphotyrosine antibody and 
substrate conversion of a HRP substrate was analyzed by colorimetry at 450 nm. Data in the graph 
represent 1 out of 3 independent experiments ± SEM. P values were calculated by student’s t-test. 
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5.2.2. Binding of MR to CD45 enhanced phosphotyrosine levels 
Intracellular substrates of CD45 are SFKs like Hck and Lyn 96 as well as JAKs 48–50. These 
kinases are involved in signal transduction pathways regulating a multitude of cellular 
events like cytokine-mediated proliferation, differentiation, cell growth, survival, and 
migration 97,98. The pathways are often regulated by phosphorylation and 
dephosphorylation of tyrosine residues associated with the activation or inactivation of 
corresponding enzymes. To investigated whether the binding of the MR to CD45 alters 
the total phosphotyrosine levels in MR-/- BM(GM-CSF) cells, BM(GM-CSF) cells were 
stimulated with complexed FcMR or isotype control for 30 min. Immediately cells were 
lysed, proteins were analyzed by SDS-PAGE and western blotting. Total 
phosphotyrosine levels were detected with a phosphotyrosine-specific antibody (Figure 
19). 
 
Figure 19: Phosphotyrosine pattern of BM(GM-CSF) cells was altered by the MR/CD45 
interaction. MR-/- BM(GM-CSF) cells were stimulated with complexed FcMR (+) or isotype control (-) for 
30 min at 37 °C. Afterwards, cells were lysed and total protein content were analyzed by SDS-PAGE 
and western blot. Phosphotyrosine residues were stained by antibody clone 4G10®. GAPDH was used 
as loading control. Representative blot from 1 out of 5 independent experiments is shown. Bars indicate 
mean intensity of phosphotyrosine proteins greater than 40 kDa relative to GAPDH intensity. 
Staining of total cell lysates of BM(GM-CSF) cells with a phosphotyrosine-specific  
antibody generated a huge band pattern over the hole range of the protein standard 
representing the spectrum of tyrosine-phosphorylated proteins within the cell lysate. 
After incubation with FcMR the pattern of phosphotyrosine-bearing proteins changed, 
with a tendency towards an increase in overall phosphorylated proteins. Thus, the 
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binding of the MR to CD45 inhibited its phosphatase activity leading to modified signal 
transduction in BM(GM-CSF) cells. 
CD45 is known to interact with JAKs and inactivating them by direct dephosphorylation 
48. Activated JAKs are important for activation of the transcriptional factor Signal 
Transducers and Activators of Transcription (STAT), which are important for cytokine 
driven signaling 99. Target genes of STAT proteins are suppressor of cytokine signaling 
(SOCS) proteins that negatively regulates cytokine signaling 100.  
We analyzed a potential influence of the MR on this signaling pathway in BM(GM-CSF) 
cells. Therefor, BM(GM-CSF) cells were stimulated with complexed FcMR or isotype 
control for 4 h or 12 h. mRNA of stimulated cells were isolated and analyzed by 
quantitative Real-time PCR (qRT-PCR) (Figure 20). 
 
Figure 20: Expression of STAT molecules and target genes were enhanced by FcMR stimulation 
of BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were stimulated with complexed FcMR or isotype 
control for 4 h or 12 h at 37 °C. Afterwards, mRNA of cells were isolated and analyzed by quantitative 
real-time PCR (qRT-PCR). Relative expression was normalized with ΔΔCT method to housekeeping 
genes HPRT (hypoxanthine phosphoribosyltransferase), PPIA (peptidylprolyl isomerase A), and TBP 
(TATA-box binding protein). Representative graph from 1 out of 3 independent experiments is shown ± 
SEM. 
0 2 4 6
SOCS3
STAT6
STAT3
STAT1
4 h isotype control
4 h FcMR
12 h isotype control
12 h FcMR
Relative Normalized Expression
Ta
rg
et
Results 
 
 47 
Stimulation of BM(GM-CSF) cells with FcMR for 4 h lead to a 2-fold increase of STAT1 
expression compared to isotype control-treated cells. After 12 h, STAT1 expression was 
further enhanced by FcMR stimulation whereas expression in control cells remained the 
same (Figure 20, first row). STAT3 expression was only increased after 12 h of FcMR 
stimulation in BM(GM-CSF) cells (2-fold) compared to controls. Independent of 
stimulation, expression levels after 4 h were the same (Figure 20, second row). At no 
time, FcMR-mediated changes in the expression of STAT6 were detectable (Figure 20, 
third row). Regarding SOCS3, stimulation of BM(GM-CSF) cells with FcMR enhanced 
expression levels on a 3-fold increase after 4 h as well as after 12 h compared to control 
cells  (Figure 20, fourth row).  
 
In summary, these experiments demonstrate that the inhibition of CD45 phosphatase 
activity in BM(GM-CSF) cells by interaction with the MR influences the JAK/STAT 
signaling in BM(GM-CSF) cells. 
5.3. FcMR-pretreatment of BM(GM-CSF) cells led to altered 
effector function of primed T cells 
APCs are important for the induction of the adaptive immunity. They process and 
present endogenous and exogenous peptides on MHC I and II, respectively. Thereby 
CD4+ and CD8+ naïve T cells get activated 8. The binding of FcMR to CD45 on 
BM(GM-CSF) cells altered intracellular signaling pathways by inhibition of CD45 
phosphatase activity (see 5.2). Therefore, it was investigated whether FcMR treatment of 
BM(GM-CSF) cells results in altered T cell effector function. 
5.3.1. IFN-γ secretion of CD4+ T cells was impaired by FcMR 
CD4+ T cells are necessary for cell-mediated immunity. Once activated, they secrete 
cytokines to recruit and activate other cells of the immune system 4. Therefore, the 
secretion of IFN-γ was analyzed after restimulation of CD4+ T cells that were initially 
primed with FcMR-pretreated BM(GM-CSF) cells. 
MR-/- BM(GM-CSF) cells were pre-treated with complexed FcMR or isotype control and 
co-cultured with antigen-specific CD4+ OT-II cells. T cells were isolated by density 
gradient centrifugation and equal cell numbers were restimulated with an anti-CD3 
antibody. Secretion of IFN-γ into the cell supernatant was analyzed by ELISA (Figure 
21). 
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Figure 21: IFN-γ secretion of antigen-specific CD4+ T cells was impaired by priming through 
FcMR-prestimulated BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were stimulated O/N with 
complexed FcMR or isotype control. After stimulation, cells were loaded with OVA antigen and co-
cultured with antigen-specific CD4+ OT-II T cells for 5 days. Primed T cells were isolated by density 
gradient centrifugation and restimulated O/N with or without an anti-CD3 antibody (αCD3). Secretion of 
IFN-γ by T cells was analyzed in the cell supernatant by ELISA. Data in the graph represent 1 out of 8 
independent experiments ± SEM. P values were calculated by student’s t-test. n.d.: not detectable 
Antigen-specific CD4+ T cells primed by BM(GM-CSF) cells that were pre-stimulated 
with isotype control secrete high amounts of IFN-γ (Figure 21, white bar). A significant 
reduction (p< 0.001) in the amount of secreted IFN-γ was measured if CD4+ T cells 
were primed by FcMR-prestimulated BM(GM-CSF) cells (Figure 21, black bar).  
 
Taken together, the treatment of BM(GM-CSF) cells with FcMR reduced the activity of 
antigen-specific CD4+ T cells to secrete IFN-γ compared to T cells activated by control 
BM(GM-CSF) cells. 
5.3.2. Cytotoxicity of CD8+ T cells was reduced by FcMR 
Activated CD8+ T cells are cytotoxic and can directly eliminate cells presenting T cell-
specific peptides on MHC I molecules 4,8.  
To assess the effect of FcMR on effector mechanisms of CD8+ T cells, the killing 
capacity of CD8+ T cells was analyzed in an in vitro cytotoxicity assay. 
MR-/- BM(GM-CSF) cells were treated with FcMR or isotype control and co-cultured 
with antigen-specific CD8+ DesTCR T cells. These cells recognize endogenous processed 
peptides presented on H-2Kb in an allogenic reaction 80, meaning that the activation of 
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these T cells is independent of antigen uptake. Primed T cells were isolated by density 
gradient centrifugation and co-cultured with differently CFSE-labeled target (RMA) and 
control (RMA-S) cells. Different ratios of T cells and target cells were assessed. The 
killing of target cells by activated T cells was analyzed by flow cytometry (Figure 22A). 
To calculate the specific killing, living cells were distinguished from death cells by 
Hoechst staining.  
 
Figure 22: Cytotoxicity and IFN-γ secretion of CD8+ T cells primed by FcMR-prestimulated 
BM(GM-CSF) cells were decreased. MR-/- BM(GM-CSF) cells were stimulated O/N with complexed 
FcMR or isotype control. Next day, BM(GM-CSF) cells were co-culture with H-2Kb-specific CD8+ 
DesTCR T cells for 3 days. Primed T cells were isolated by density gradient centrifugation and used for 
in vitro cytotoxicity assay (A) or restimulation (B). Data in the graphs represent (A) the mean of 3 or (B) 
1 representative experiment out of 3 independent experiments ± SEM. P values were calculated by 
student’s t-test. P values were calculated by student’s t-test. (A) Differently CFSE-labeled target (RMA) 
and control (RMA-S) cells were co-cultured with isolated T cells O/N in different T cell/ target cell ratios. 
Killing of target cells was analyzed by flow cytometry. Dead cells were stained with Hoechst. (B) Isolated 
T cells were restimulated O/N with anti-CD3 antibody. Secretion of IFN-γ was analyzed by ELISA using 
cell supernatant. 
The percentage of cytotoxicity was raised with increasing T cell:target cell ratios (Figure 
22A). CD8+ T cells primed by FcMR-treated BM(GM-CSF) cells exhibited a significantly 
reduced cytotoxicity compared to T cells primed by isotype control-treated BM(GM-
CSF) cells (Figure 22A, black graph). 
The secretion of IFN-γ by primed CD8+ T cells after restimulation was also analyzed. 
For this purpose, T cells primed by FcMR- or isotype control pretreated BM(GM-CSF) 
cells were restimulated with an anti-CD3 antibody and IFN-γ cytokine secretion was 
analyzed by ELISA (Figure 22B). The amount of secreted IFN-γ was reduced when T 
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cells were primed by FcMR-treated BM(GM-CSF) cells (Figure 22B, black bar) 
compared to T cells primed by isotype control-teated BM(GM-CSF) cells. 
 
In summary, the activity of antigen-specific CD8+ T cells was inhibited by FcMR 
treatment of BM(GM-CSF) cells as seen in the overall cytotoxicity as well as in the 
secreted IFN-γ level. 
5.4. Soluble mannose receptor (sMR) was detectable in cell 
culture supernatant of BM(GM-CSF) cells 
Treatment of BM(GM-CSF) cells with the recombinant MR construct (FcMR) reduced 
CD45 phosphatase activity in BM(GM-CSF) cells in vitro causing a reduced IFN-γ 
secretion of antigen-specific CD4+ T cells and impaired cytotoxic activity of antigen-
specific CD8+ T cells that were primed by FcMR-treated BM(GM-CSF) cells (Figure 21 
and Figure 22, respectively). These results show that FcMR leds to a tolerogenic effect 
on BM(GM-CSF) cells presumably via the inhibition of CD45 activity. In vivo, an 
equivalent to the recombinant MR construct might be the soluble MR (sMR). The sMR 
is generated by cleavage of metalloproteases and comprise the complete extracellular part 
of the MR in a functional form 65. The function of the soluble form of the MR is still 
under investigation. Based on the results of experiments with the recombinant MR a 
similar role of the sMR was proposed. To further investigate this issue, it was tested first 
whether the BM(GM-CSF) cells also generate a soluble form of the MR. 
BM(GM-CSF) cells were generated from wt and MR-/- mice. On day 7, cells were 
replated in a defined concentration of 2*106 cells/mL and after 5-7 days the supernatant 
was collected. Cells were lysed and protein content of cell lysates and supernatants were 
separated by SDS-PAGE. Western blots were stained with an anti-MR antibody (Figure 
23). 
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Figure 23: Wt BM(GM-CSF) cells released sMR into the supernatant. BM(GM-CSF) cells of wildtype 
(wt) and MR-/- mice were cultured for 7 days. Cells were replated in a concentration of 2*106 cells per mL 
medium for 5 days. Supernatant was collected and cells lysed. Both were analyzed by SDS-PAGE and 
western blot. Cellular MR (cMR) and soluble MR (sMR) were detected by an antibody specific for the 
extracellular part of the MR (clone MR5D3). Calnexin was used as loading control for cell lysates. 
Representative blot from 1 out of 3 independent experiments is shown. 
 
In cell lysates of wt BM(GM-CSF) cells the cellular MR (cMR) could be detected at 170-
180 kDa (Figure 23). In the supernatant of these cells a truncated form (~10-20 kDa 
smaller) of the MR was identified corresponding to the sMR 101. Neither cMR nor sMR 
could be detected in cell lysates or supernatant of MR-/- BM(GM-CSF) cells, respectively. 
These data point out that sMR was generated by MR-expressing BM(GM-CSF) cells in 
vitro as described by Martinez-Pomares (1998) 65. 
5.5. Influence of sMR on BM(GM-CSF) 
As the recombinant protein of the MR has a tolerogenic effect on MR-/- BM(GM-CSF) 
cells next it was investigated whether the sMR influenced these cells in a similar manner. 
For this purpose, MR-/- BM(GM-CSF) cells were incubated with sMR-containing 
supernatant of wt BM(GM-CSF) cells. As a control, supernatant of MR-/- BM(GM-CSF) 
cells without sMR was used. We analyzed the CD45 phosphatase activity and total 
phosphotyrosine levels of the stimulated cells as described in 5.2 (see also 4.2.6 and 4.2.7) 
(Figure 24). 
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Figure 24: CD45 phosphatase activity was decreased and phosphotyrosine levels were changed 
by stimulation with sMR-containing supernatant. (A) MR-/- BM(GM-CSF) cells were stimulated with 
sMR-containing (w/ sMR) or control (w/o sMR) supernatant for 1 h. Cells were lysed and CD45 was 
immunoprecipitated by an anti-CD45 antibody. Protein was coupled to protein A/G beads and 
phosphatase activitiy was measured by substrate conversion of alkaline phosphatase substrate 4-
nitrophenyl phosphate. Substrate conversion was measured by colorimetry at 405 nm. Activity was 
blocked by the phosphatase inhibitor SF1670 (inh, white bars). As a control, no antibody was used for 
immunoprecipitation (Ctrl). Data in the graphs represent the mean of 3 independent experiments ± SEM. 
P values were calculated by student’s t-test. (B) MR-/- BM(GM-CSF) cells were stimulated with sMR-
containing (+) or control (-) supernatant for 30 min at 37 °C. Afterwards, cells were lysed and total 
protein content was analyzed by SDS-PAGE and immunoblotting (left). Phosphotyrosine residues were 
stained by anti-phosphotyrosine antibody (clone 4G10). GAPDH was used as loading control. 
Representative blot from 1 out of 5 independent experiments is shown. Bars indicate mean intensity of 
phosphotyrosine proteins greater than 40 kDa relative to GAPDH intensity. 
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BM(GM-CSF) cells that were stimulated with supernatant containing sMR (w/ sMR) had 
a reduced CD45 phosphatase activity in comparison to cells stimulated with control (w/o 
sMR) supernatant (Figure 24A, black bars). Furthermore, the pattern of 
phosphotyrosine-bearing proteins of BM(GM-CSF) cells stimulated with sMR-containing 
supernatant was also slightly altered (Figure 24B), demonstrating that the influence of 
the binding of sMR to CD45 on BM(GM-CSF) cells was comparable to the binding of 
FcMR to CD45. 
5.6. Enhanced T cell effector function after sMR-pretreatment of 
BM(GM-CSF) 
The activity of CD45 and downstream signaling pathways were changed by sMR-
containing supernatant in a similar way like the recombinant MR (FcMR) (see Figure 
17, Figure 19 and Figure 24). Therefore, it was further analyzed whether the 
supernatant of wt BM(GM-CSF) cells (including sMR) has also an effect on T cell 
effector function through pretreatment of BM(GM-CSF) cells.  
MR-/- BM(GM-CSF) cells were incubated with supernatant of wt or MR-/- BM(GM-CSF) 
cells and co-culture with antigen-specific CD4+ OT-II T cells. Primed T cells were 
isolated by density gradient centrifugation and restimulated O/N with anti-CD3 
antibody. IFN-γ secretion of restimulated CD4+ was analyzed by ELISA (Figure 25A) 
For CD8+ T cells, MR-/- BM(GM-CSF) cells were incubated with supernatant of wt or 
MR-/- BM(GM-CSF) cells co-cultured with antigen-specific CD8+ DesTCR T cells. 
Primed T cells were isolated by density gradient centrifugation and either restimulated 
O/N with anti-CD3 antibody or used in in vitro cytotoxicity assay. IFN-γ secretion of 
restimulated CD8+ T cells was analyzed by ELISA (Figure 25C) and killing capacity by 
flow cytometry (Figure 25B). 
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Figure 25: Treatment of BM(GM-CSF) cells with sMR-containing supernatant enhanced CD4+ and 
CD8+ T cell effector functions. MR-/- BM(GM-CSF) cells were stimulated O/N with sMR-containing (w/ 
sMR; black graphs/bars) or control (w/o sMR; white graphs/bars) supernatant. After stimulation, cells 
were either loaded with OVA antigen and co-cultured with antigen-specific CD4+ OT-II T cells for 5 days 
(A) or co-culture with H-2Kb-specific CD8+ DesTCR T cells for 3 days (B, C). Primed T cells were 
isolated by density gradient centrifugation and used for restimulation (A, C) or in vitro cytotoxicity assay 
(B). Data in the graphs represent (A, C) 1 experiment out of 3 independent experiments or (B) the mean 
of 3 independent experiments ± SEM. P values were calculated by student’s t-test. (A, C) Isolated T 
cells were restimulated O/N with anti-CD3 antibody. Secretion of IFN-γ was analyzed by ELISA using 
cell supernatants. (B) Differently CFSE-labeled target (RMA) and control (RMA-S) cells were co-cultured 
with isolated T cells O/N in different T cell/ target cell ratios. Killing of target cells were analyzed by flow 
cytometry. Dead cells were stained with Hoechst.  
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In contrast to the pretreatment with recombinant MR, antigen-specific CD4+ OT-II cells 
activated by MR-/- BM(GM-CSF) cells pretreated with sMR-containing supernatant 
secreted significantly higher amounts of IFN-γ (Figure 25A). Additionally, the 
cytotoxicity (Figure 25B) and secretion of IFN-γ (Figure 25C) by CD8+ antigen-
specific T cells were enhanced after priming by BM(GM-CSF) cells treated with sMR-
containing supernatant  
5.7. Altered T cell effector functions were not due to differences 
in T cell activation  
Based on the results in Figure 21, Figure 22 and Figure 25, the recombinant FcMR 
seems to have a tolerogenic effect on BM(GM-CSF) cells whereas the sMR seems to 
have a immunstimulatory effect. To rule out differences in the activation capacity of 
BM(GM-CSF), surface marker, antigen uptake of BM(GM-CSF) cells and proliferation 
of T cells were analyzed.  
5.7.1. Expression of surface molecules was not changed by FcMR or sMR  
Binding of the MHC/peptide complex to the TCR is crucial for T cell priming. One 
additional signal to activate naïve T cells is the interaction of costimulatory molecules 
expressed by the APC with ligands on T cells surface 1,3,7. This interaction promotes T 
cell activation. In contrast to activation, also inhibitory molecules are important to 
supress and terminate ongoing immune responses. To investigated if differences in T cell 
effector phase by FcMR and sMR-containing supernatant was due to altered activation 
by BM(GM-CSF) cells, first, the expression of MHC molecules (MHC I, MHC II), 
costimulatory molecules (CD40, CD80, CD86) as well as coinhibitory molecules (B7H1, 
B7DC) on the surface of BM(GM-CSF) cells were analysed after treatment with FcMR 
or sMR-containing supernatant. 
BM(GM-CSF) cells were incubated in the presence of either FcMR and isotype control 
or supernatant of wt and MR-/- BM(GM-CSF) cells. Afterwards, surface molecules were 
stained with antigen-specific fluorescent-labeled antibodies and analyzed by flow 
cytometry (Figure 26).  
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Figure 26: Expression of surface molecules on BM(GM-CSF) cells after FcMR or sMR-containing 
supernatant treatment was not changed. MR-/- BM(GM-CSF) cells were stimulated O/N with either 
complexed FcMR (red) and isotype control (black) or sMR-containing (red) and control supernatant 
(black). After stimulation, cells were scraped off and stained with fluorescent-labeled antibodies against 
(A) MHC molecules (MHC I, MHC II), (B) costimulatory molecules (CD40, CD80, CD86) or (C) 
coinhibitory molecules (B7H1, B7DC). Expression of surface molecules was analyzed by flow cytometry. 
Unstained cells were used as a control (filled grey). Representative graphs from 1 out of 9 independent 
experiments are shown. 
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BM(GM-CSF) cells expressed MHC I as well as MHC II molecules. Their expression 
was neither changed by FcMR nor by supernatant treatment (Figure 26A). The same 
was detected for costimulatory molecules. CD40, CD80, and CD86 were expressed but 
neither regulated by FcMR nor by sMR-containing supernatant (Figure 26B). The 
inhibitory molecules B7H1 (PD-L1) and B7DC (PD-L2) could be detected in BM(GM-
CSF) cells but their expression was not influenced by treatment with FcMR or sMR-
containing supernatant (Figure 26C).  
 
Therefore, diminished and enlarged T cell effector functions by FcMR and sMR-
containing supernatant treatment of BM(GM-CSF) cells, respectively, were not caused by 
differences in the expression of surface molecules.  
5.7.2. MR treatment of BM(GM-CSF) cells do not provoke differences in 
antigen uptake  
T cell activation is mainly based on the recognition of MHC/peptide complexes by 
TCRs. Therefore, peptides have to be processed and loaded on MHC molecules 8. The 
surface expression of MHC molecules was not changed (see Figure 26A) whether 
BM(GM-CSF) cells were treated with recombinant MR or sMR-containing supernatant. 
Nevertheless, different peptides could be presented leading to a difference in effector cell 
activation. CD8+ T cells in this system were activated by endogenous peptides of the 
BM(GM-CSF) cells and, thereby, independent of specific antigen uptake 80. However, 
antigen-specific OT-II CD4+ T cells were activated by an extracellular antigen (OVA) 
and, therefore, OVA had to be taken up by pinocytosis by the BM(GM-CSF) cells. To 
exclude a different activation of CD4+ T cells due to altered antigen uptake by MR-
treated BM(GM-CSF) cells the OVA uptake of MR-/- BM(GM-CSF) cells after treatment 
with FcMR or sMR-containing supernatant was analyzed. To validate the uptake 
mechanism also for receptor-mediated endocytosis, the uptake of transferrin (Trf) by the 
transferrin receptor, which is expressed by MR-/- BM(GM-CSF), was additionally 
analyzed.  
MR-/- BM(GM-CSF) cells were stimulated with FcMR or supernatant containing sMR 
and the corresponding controls and pulsed with fluorescent-labeled OVA or Trf. 
Antigen uptake was analyzed by flow cytometry (Figure 27).  
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Figure 27: Pinocytosis and receptor-mediated endocytosis was not altered due to FcMR or sMR-
conatining supernatant treatment of BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were stimulated 
with either (A) FcMR (red) and isotype control (black) or (B) sMR-containing (red) and control 
supernatant (black) O/N. Then, cells were replated and pulsed with 250 ng/mL OVA-Alexa Fluor® 647 or 
5 µg/mL Trf-Alexa Fluor® 647 for 15, 30, or 60 min. Remaining antigen was washed away and uptake of 
antigen was analyzed by flow cytometry. Cells incubated in the absence of antigen were used as a 
control (filled grey). Representative graphs from 1 out of 4 independent experiments are shown. 
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The uptake of OVA by BM(GM-CSF) cells increased over time. Nevertheless no 
differences could be detected between cells stimulated with FcMR (red graph) and the 
isotype control (black graph) (Figure 27A, upper row). Also the incubation with 
supernatant (w/ sMR vs. w/o sMR) showed no influence on OVA uptake (Figure 27B, 
upper row). Transferrin was taken up within the first 15 minutes and its concentration 
only slightly increased over time. No differences in the receptor-mediated uptake of 
antigen were detected neither after FcMR, nor after supernatant treatment (Figure 27A 
and Figure 27B, bottom row). 
5.7.3. IL-2 secretion and proliferation of T cells were not changed by MR 
treatment of BM(GM-CSF) cells 
BM(GM-CSF) cells stimulated with the MR (FcMR or sMR-containing supernatant) take 
up antigens and express surface molecules in the same manner like control cells. 
However, T cells primed by MR-treated BM(GM-CSF) cells show altered activities. 
Therefore, it was analyzed whether the different activities of T cells were due to changed 
cytokine secretion or proliferation of the cells. Once activated by APCs, T cells start to 
secrete IL-2. IL-2 acts via an autocrine mechanism and facilitate the proliferation of T 
cells 4.  
First, the IL-2 secretion of CD4+ OT-II and CD8+ DesTCR T cells was investigated. 
MR-/- BM(GM-CSF) cells were cultured in the presence of FcMR or sMR-containing 
supernatant (and corresponding controls) and co-cultured with antigen-specific T cells. 
24 h after co-culturing, supernatants were isolated and IL-2 secretion was measured by 
ELISA (Figure 28). 
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Figure 28: IL-2 secretion of primed antigen-specific T cells were not changed by MR treatment of 
BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were stimulated O/N with either complexed FcMR and 
isotype control (left panel) or sMR-containing and control supernatant (right panel). After stimulation, 
cells were loaded with OVA antigen (in case of CD4+ T cells) and co-cultured with antigen-specific CD4+ 
OT-II or CD8+ DesTCR T cells for 24 h. Secretion of IL-2 by T cells were analzyed in the cell 
supernatant by ELISA. As a control, T cells were cultured without BM(GM-CSF) cells (left bars). Data in 
the graphs represent 1 experiment out of 4 independent experiments ± SEM. n.s.: not significant 
 
 
 
 
 
T cells cultured without BM(GM-CSF) cells (Figure 28, left bars) as well as BM(GM-
CSF) cells alone (data not shown) did not secrete measurable amounts of IL-2. When T 
cells were co-cultured with BM(GM-CSF) cells, IL-2 was secreted (Figure 28, right 
bars). However, no differences between MR-treated BM(GM-CSF) cells (Figure 28, 
black bars) and control cells (Figure 28, white bars) could be detected, neither for 
FcMR-treated cells, nor for sMR-containing supernatant-treated cells (Figure 28). 
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Next, we analyzed the proliferation rate of primed T cells. FcMR- or supernatant-
prestimulated BM(GM-CSF) cells were co-cultured with CFSE-labeled antigen-specific 
CD4+ OT-II and CD8+ DesTCR T cells. Three days later, T cells were stained with 
fluorescent-labeled antibodies against CD4 or CD8 and cells were analyzed by flow 
cytometry. During proliferation CFSE is diluted equally between daughter cells with each 
new generation. Thus, the proliferation of T cells is depicted by a CFSE dilution profile 
in which each generation is represented through one peak. As a control, cells cultured in 
the absence of BM(GM-CSF) cells were used (Figure 29, filled grey). 
 
Figure 29: Proliferation of antigen-specific T cells was not changed due to MR treatment of 
BM(GM-CSF) cells. MR-/- BM(GM-CSF) cells were stimulated O/N with either FcMR and isotype control 
or sMR-containing (w/ sMR) and control (w/o sMR) supernatant. After stimulation, cells were either 
pulsed with OVA antigen and co-cultured with CFSE-labeled OVA-specific CD4+ OT-II T cells (A) or co-
culture with CFSE-labeled H-2Kb-specific CD8+ DesTCR T cells directly (B) for 3 days. Antigen-specific 
T cells were stained by CD4 or CD8 antibody, respectively. Proliferation of T cells were analyzed by flow 
cytometry. T cells cultured in the absence of BM(GM-CSF) cells were used as a control (filled gray). 
Representative graphs from 1 out of 7 independent experiments are shown. 
The experiment showed CD4+ as well as CD8+ T cells proliferate equally when primed 
by MR-treated or control BM(GM-CSF) cells (Figure 29, left panel). Furthermore, also 
the stimulation with sMR-containing supernatant compared to control did not influenced 
proliferation of antigen-specific primed CD4+ and CD8+ T cells (Figure 29, right panel).  
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5.8. In v ivo  sMR was upregulated after high-fat diet (HFD) in 
mice and in obese patients 
In vitro, stimulation of BM(GM-CSF) cells with either FcMR or supernatant containing 
sMR resulted in different T effector functions of primed antigen-specific CD4+ and 
CD8+ T cells. In vivo, sMR was found in murine 65 and human 68 serum offering the 
possibility that sMR can have an effect on cells via interaction with CD45 over distance. 
So far, the function of sMR is still unknown. In 2013, Rødgaard-Hansen et al. reported 
an upregulation of sMR in sepsis and liver disease in humans 68 and mentioned for the 
first time a disease-related sMR regulation. In cooperation with Bruno Guigas of the 
University Medical Center of Leiden we could show that analysis of adipose tissue (AT) 
of MR-deficient mice fed a high-fat diet (HFD) showed altered ratios of MΦ 
subpopulations and an increased recruitment of other immune cells like eosinophiles and 
neutrophiles. Furthermore, the MR-/- mice depicted a reduced fat accumulation of e.g. 
gonadal, visceral, and subcutaneous fat after HFD (unpuplished data). Further studies 
showed that in human AT a subpopulation of macrophages (ATM) highly expressing the 
MR is associated with less AT inflammation 102,103. All these data proposed a direct 
correlation between MR expression and HFD induced obesity. To investigate this 
hypothesis the amount of sMR in serum samples of mice fed 12 weeks a low- or high-fat 
died and of lean and obese humans was analyzed.  
First, an assay to identify sMR in serum samples was developed. sMR was 
immunoprecipitated with an anti-MR antibody and eluates were analyzed by SDS-PAGE 
and western blot (Figure 30). 
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Figure 30: sMR was found in wt mouse serum and was elevated after HFD. (A) Serum samples of 
wildtype (wt) or MR-/- mice were precleared by protein A/G beads. An antibody specific for the 
extracellular part of the MR (clone MR5D3) was coupled to protein A/G beads. sMR of precleared 
samples were immunoprecipitated by antibody-coupled protein A/G beads. Beads without antibody were 
used as a control. Eluates were analyzed by SDS-PAGE and western blot. sMR were detected by an 
biotin-labelled antibody specific for the MR (clone MR5D3). Representative blot from 1 out of 4 
independent experiments is shown. (B) Serum samples of 5 mice fed a low-fat died (LFD) or 6 mice fed 
a high-fat died (HFD) for 12 weeks were analyzed as described in (A). Relative intensities of MR bands 
on western blot were normalized to the mean of relative quantities of LFD samples. Data in the graphs 
represent the mean of 5 (LFD) or 6 (HFD) individual ± SEM. 
We could specifically immunoprecipitated sMR from serum of wt mice but not from 
serum of MR-/- mice (Figure 30A). If no antibody was used in the precipitation sMR 
could not isolated neither in wt nor in MR-/- serum.  
We used the established assay to immunoprecipitate sMR from serum samples of 5 low-
fat diet (LFD) and 6 high-fat diet (HFD) mice. Increased amounts of sMR were detected 
in serum samples of mice fed HFD compared to LFD mice (Figure 30B). 
 
In addition, sMR levels in the human serum samples were analyzed (Figure 31).  
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Figure 31: sMR was found in human serum and was elevated in obese patients. (A) A human 
serum sample was precleared by protein A/G beads. An antibody specific for the extracellular part of the 
MR (clone 7-450) was coupled to protein A/G beads. sMR of precleared samples were 
immunoprecipitated by antibody-coupled protein A/G beads. Beads without antibody were used as a 
control. Eluates were analyzed by SDS-PAGE and western blot. sMR were detected by an biotin-
labelled antibody specific for the MR (clone 15-2). Representative blot from 1 out of 2 independent 
experiments is shown. (B) Serum samples of 12 lean and 14 obese patients were analyzed as 
described in (A). Relative intensities of MR bands on western blot were normalized to the mean of 
relative quantities of LFD samples. Data in the graphs represent the mean of 12 (lean) or 14 (obese) 
patients ± SEM. P values were calculated by student’s t-test. 
 
An immunoprecipitation of sMR from human serum sample was also possible. sMR was 
detected in western blot when an anti-human MR antibody was used in comparison to 
the same serum sample without antibody used in the precipitation (Figure 31A). 
Analysis of serum samples from 12 lean and 14 obese patients revealed enhanced sMR 
levels in obese humans compared to lean patients (Figure 31B). 
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6. Discussion 
Antigen presenting cells (APCs) are essential to initiate an effective antigen-specific 
immune response when inflammatory processes were not completely eliminated by the 
innate immune system 8. In addition, APCs are also important for the induction of 
immune tolerance 104,105. Balancing immune response and tolerance, the intracellular 
signaling pathways leading to T cell activation versus T cell tolerance and involved 
receptor-proteins are still under investigation 106. 
The mannose receptor (MR) is one of these receptors. It is expressed by a variety of cells 
including MΦs, non-vascular endothelium, a multitude of immune inhibitory cells and 
DCs, the major cell type at the cross talk between innate and adaptive immune response 
54,55,76,78,107. As an endocytic receptor on the cell surface of DCs, the MR induces immunity 
under inflammatory conditions through the uptake and processing of foreign 
extracellular antigens 54. Under non-inflammatory conditions, the MR on DCs provokes 
CD8+ T cell tolerance by binding to CD45 on T cells. The interaction between MR and 
CD45 inhibits CD45 phosphatase activity leading to T cell re-programming and the 
upregulation of CTLA-4, which in turn inhibits CD8+ T cell cytotoxicitiy 79. 
The present study demonstrates that CD45 on the surface of BM(GM-CSF) cells is 
bound by the MR, reducing its phosphatase activity and thereby altering BM(GM-CSF) 
cell behavior leading to changes in effector function of primed antigen-specific T cells. 
Additionally, this study presents a correlation of MR expression and HFD-induced 
obesity in mice and human. 
6.1. The MR as binding partner of CD45 
CD45 is a leukocyte-specific glycoprotein expressed in a cell-type specific pattern 
depending on differentially expressed exons and developmental stage of the cell 22. The 
MR was discovered as a binding partner of CD45 by Martinez-Pomares et al. (1999). 
They observed a binding of the CR domain of the MR to two of the low molecular 
weight isoforms (~180 kDa) of CD45 expressed by marginal zone metallophilic MΦs 
and subcapsular sinus MΦs in secondary lymphoid organs and follicular DCs 53. Schuette 
et al. (2016) showed an interaction of the MR with CD45 on CD8+ T cells. Under non-
inflammatory conditions, these cells express an intermediate molecular weight (~200 
kDa) isoform of CD45 that was bound by the MR 79. In this work, we were able to 
demonstrate that a recombinant MR construct comprising the CR, FN II and the 
CTLD1-2 domains of the MR (FcMR) also binds to CD45 of BM(GM-CSF) cells 
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expressing the lowest molecular weight isoform CD45R0 (Figure 16). Due to the fact 
that CD45 is expressed by all leukocytes in a cell-type specific pattern and the interaction 
of MR with CD45 was discovered in different cells expressing different isoforms, this 
raises the question which isoform is exactly bound by the MR and whether the 
expression of a specific isoform has an influence on the effect of the MR on the cell. 
 
The extracellular part of CD45 differs in size, shape, and charge due to various isoforms. 
In BM(GM-CSF) cells no alternatively spliced exon could be detected neither in western 
blot analysis nor in flow cytometry (Figure 14 and Figure 15). This shows that 
BM(GM-CSF) cells express the lowest molecular isoform CD45R0. Although, Martinez-
Pomares et al. 53 and Schuette et al. 79 showed an interaction of the CR domain of the MR 
with higher molecular weight isoforms of CD45, however, the FcMR binds to CD45R0 
in BM(GM-CSF) cells (Figure 16). The domains common to all isoforms are the CR 
and FN III domain. An important function for these domains was already suggested 
based on the high variability of sequence divergence in rodents, cattle, and primates 108.  
A disruption of the binding of MR to CD45 was observed after peptide N-glycanase F 
(PNGase F) treatment 53. PNGase F releases intact N-glycans by cleavage between the 
innermost N-acetylglucosamine and asparagine. The CR and the FN III domains of 
CD45 are N-glycosylated, whereas the alternatively spliced exons A, B, and C are O-
glycosylated 23. These support the hypothesis that the MR might bind to the CR or FN 
III domain of CD45. Furthermore, this indicates that cell-specific glycosylation of CD45 
is indeed responsible for the binding of MR. 
The recognition of translational modifications of CD45 can explain why a binding of 
FcMR in BM(GM-CSF) cells was only detected with the upper of two CD45-specific 
bands (170-190 kDa) in our western blot analysis (Figure 16). The two bands in western 
blot might indicate two different glycosylated forms of CD45R0 because differences in 
size through glycosylation might result in a different migration in SDS-PAGE.  
We also generated transient chinese hamster ovarian (CHO) cell lines expressing only 
one specific murine CD45 isoform and analyzed the binding of FcMR to CD45 (data not 
shown). Although, CD45 isoforms could be detected in CHO cells by isoform-specific 
antibodies in western blot analysis and flow cytometry, no interaction of FcMR with 
CD45 was detected. Due to cell type-specific expression of glycosylation enzymes these 
results further support the assumption that posttranslational modifications especially 
glycosylation of CD45 are recognized by the MR. 
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6.2. The importance of CD45 for APCs 
The function of CD45 in lymphocytes has been intensely studied but in APCs the 
function is still elusive 109. As a protein tyrosine phosphatase, CD45 has a pivotal role in 
signal transduction and has been linked to many autoimmune diseases 108.  
In MΦs, CD45 is associated with adhesion 95,110. It was reported that CD45-deficient 
mice have a defective β2-integrin-dependent adherence. CD45 co-localize with β2 
integrin and Src kinases in focal contact sites 95 and was reported to be involved in two 
steps of integrin signaling. First, CD45 regulates paxillin degradation in MΦs 110. Paxillin 
is essential in the signaling scaffold recruitment early in integrin adhesion 111. Second, 
CD45 limits the activation of Src kinases by dephosphorylation of the autocatalytic site. 
In CD45-/- MΦs it has been described that the kinases Hck and Lyn are 
hyperphosphorylated and hyperactivated 95. Our results show that the binding of FcMR 
to CD45 as well as stimulation with sMR-containing supernatant inhibits CD45 
phosphatase activity in BM(GM-CSF) cells (Figure 17 and Figure 24) and indicates 
indeed an enhanced overall tyrosine phosphorylation of proteins (Figure 19 and Figure 
24).  
Antigen-specific T cells primed by FcMR- or sMR-containing supernatant-treated 
BM(GM-CSF) cells exhibit immune inhibitory or immune stimulatory capacity, 
respectively. The adhesion between APCs and T cells is important for the priming of T 
cells. A long-lasting interaction between APCs and T cells is necessary for efficient T cell 
priming whereas a short contact of APC and T cell has been postulated to induce 
tolerance 112,113. A modified adhesion through MR-mediated inhibition of CD45 activity 
might be a reason for changed T cell effector function. Nevertheless it would not explain 
the opposed influence of FcMR and sMR-containing supernatant because both inhibited 
CD45 phosphatase activity in our experiments. 
6.1. MR influence on priming capacity of APCs 
Our data show that the binding of FcMR to CD45 in BM(GM-CSF) cells results in 
diminished CD4+ and CD8+ T cell effector function indicated by reduced IFN-γ 
secretion of primed antigen-specific T cells after restimulation (Figure 21) and 
decreased cytotoxic capacity of CD8+ T cells (Figure 22A). In contrast, the treatment of 
BM(GM-CSF) cells with supernatant containing sMR increased the immunogenic 
phenotype of primed antigen-specific T cells. The cytokine secretion of CD4+ T cells 
primed by BM(GM-CSF) cells treated with sMR-containing supernatant is elevated 
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(Figure 25A) and cytotoxicity of CD8+ T cells is enhanced (Figure 25B). Thus, FcMR 
and sMR-containing supernatant seem to have opposing effects on BM(GM-CSF) cells 
which might be due to different priming of T cells. 
 
The function of activated T cells regarding immunity versus tolerance is determined by 
the balance between immune stimulatory and inhibitory signals. 
One important signal for the priming of T cells is the presentation of antigen on MHC 
molecules 7. An altered antigen uptake might be causal for the differences between 
FcMR- and sMR-containing supernatant-mediated effector functions. Uptake of soluble 
protein and apoptotic cellular antigens is regulated by small GTPases that control vesicle 
trafficking in APCs. Inhibition of small GTPases correlates with defects in activating 
antigen-specific T cells 114,115. Through integrin-mediated signaling chemical signals are 
transmitted into the cell (outside-in signaling). These signals provide a basis for 
responding to other inputs including those transmitted by growth-factor or G-protein-
coupled receptors and thereby has an influence on regulation of immune system activity 
and inflammation 111. In this study, an impact of the MR on antigen uptake and 
processing could not be observed. Neither pinocytosis nor receptor-mediated 
endocytosis were diminished or enhanced by FcMR or sMR-containing supernatant 
(Figure 27). Furthermore, the expression of MHC molecules remains the same after 
FcMR or sMR-containing supernatant treatment of BM(GM-CSF) cells (Figure 26A). 
These results additionally provide the evidence that an influence of the MR on CD45 in 
context of integrin-mediated adhesion might be unlikely. Nevertheless, the adhesion of 
MR-treated cell has to be considered. 
 
Costimulatory signals provided by APCs are another critical determinant for T cell 
activation 7,116. Signals arising from costimulatory and coinhibitory molecules dedicate 
activation of T cells. In correlation between CD45 and costimulation has been described 
by Thiel at al. (2015). It was reported that CD45-/- DCs are slightly pre-activated 
indicated by enhanced expression of costimulatory molecules 109. We considered the 
expression of costimulatory (CD40, CD80, CD86) and coinhibitory molecules (B7H1, 
B7DC) on FcMR- or supernatant-treated BM(GM-CSF) cells determined however no 
up- or downregulation (Figure 26B and Figure 26C). According to that, MR-mediated 
inhibition of CD45 phosphatase activity has no influence on costimulation provided by 
APCs. 
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Other groups described an association of CD45 with cytokine secretion in myeloid cells 
34–36. Cytokines releases by APCs are important to dictate development of specialized T 
effector cells 7. An increased secretion of pro-inflammatory cytokines (TNFalpha, IL-6) 
was reported for CD45-deficient BMDCs and splenic DCs upon TLR3 and TLR9 
stimulation 36. Montoya et al. (2006) demonstrate that CD45-/- splenic DCs offered a 
decreased type I IFN secretion (anti-inflammatory) in response to lymphocytic 
choriomeningitis virus 35. This versatile effect of CD45 on the secretion of different 
cytokines was further supported by Cross et al. (2008) which described CD45 as negative 
regulator of MyD88-dependent TLR signalling and as positive regulator of MyD88-
independent TLR signalling 34. We hypothesized an relationship of cytokine secretion by 
MR-treated BM(GM-CSF) cells and the down-regulation of CD45 activity. It was 
investigated if FcMR and sMR-containing supernatant treatment facilitates different 
cytokine profiles in BM(GM-CSF) cells but TNFalpha was even less secreted by our cells 
and IL-6 secretion was not influenced under non-inflammatory conditions (data not 
shown). Even stimulation of BM(GM-CSF) cells by TLR1/2 (Pam3Csk4), TLR4 (LPS), 
and TLR9 (CpG) agonist did not altered TNFalpha and IL-6 secretion (data not shown). 
 
Because both FcMR and sMR-containing supernatant stimulation did not influence 
antigen-uptake and –presentation, costimulation, and cytokine secretion of APCs the 
activation capacity of BM(GM-CSF) cells per se is not the reason for diverse effects on T 
effector function. This is additionally supported by the fact that proliferation (Figure 
29) and IL-2 secretion of T cells primed by MR-stimulated BM(GM-CSF) cells (Figure 
28) showed no variation at all. 
6.2. Diverse effects of FcMR and sMR on BM(GM-CSF) cells 
How FcMR and sMR-containing supernatant could have such opposing effects on 
BM(GM-CSF) cells remains elusive. 
The phosphatase activity of CD45 is inhibited by dimerization 18. CD45 is expressed at 
different developmental and activation stages in multiple, highly conserved isoforms 18. 
The homodimerization efficiencies of all isoforms are different 117 but in vitro the various 
isoforms showed similar PTP activity 118. For CD45R0, it was described that this isoform 
homodimerizes more easily than other isoforms 108.  
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Experiments in T cells with recombinant CD45 comprising the cytoplasmic domain of 
CD45 fused to the ligand-binding domain of epidermal growth factor receptor (EGFR) 
demonstrated that forced dimerization of an intracellular part of CD45 decreased TCR 
signaling 24. Additional research revealed a specific juxtamembrane ‘wedge’ motif to be 
involved in dimerization of CD45 18 Majeti et al. (2000) generated a constitutively active 
form of CD45 by inactivate the inhibitory wedge motif by an inactivating point mutation 
(CD45E613R). This point mutation leads to an autoimmune syndrome in mice 
resembling human systemic lupus erythematosus (SLE) 28. These results suggest a 
mechanism that might regulate CD45 phosphatase activity by ligand-mediated 
dimerization.  
 
At this point, one must focus on the addition of MR in our experiments. We used either 
purified recombinant MR (FcMR) or supernatant of cells generating a soluble form of 
the MR (sMR). In all experiments, FcMR had to be complexed by an anti-human 
antibody that binds to the fused human IgG1 Fc part in the recombinant protein. The 
complexation enables a multimerization of FcMR. If CD45 homodimerizes autonomous 
the binding of complexed FcMR might facilitate an enhanced dimerization of CD45 
resulting in a strong decreased CD45 phosphatase activity (Figure 32, middle) similar to 
cell membrane-bound MR (cMR). Schuette et al. (2016) showed that interaction of cMR 
from wildtype BMDCs reduced CD45 phosphatase activity in CD8+ T cells by direct 
interaction with CD45 compared to CD8+ T cells that were co-cultured with MR-
deficient BMDCs 79. Membrane-associated proteins, such as the MR, clustere into 
“protein islands” in the cell 119. Therefore, the clustered cMR binds to CD45, stabilizing 
the homodimerization and decreasing CD45 phosphatase activity (Figure 32, left).  
In contrast to the purified FcMR, the sMR was applied as a component of cell 
supernatant. No further supplement was directly added to complex sMR in the 
supernatant. After independent homodimerization of CD45, which leads to an inhibition 
of CD45 phosphatase activity, the conformation might not be stabilized by sMR as it 
could be in case of complexed FcMR (Figure 32, right). Thus, the inhibition of CD45 
phosphatase activity is neither enhanced nor prolonged. 
The different inhibition of CD45 phosphatase activity concerning strength and duration 
of inhibition could influence the BM(GM-CSF) cells in different manner.  
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Whereas FcMR contains the CR, FN II, and CTLD1-2 domain of the MR, the sMR 
comprises also CTLD3-8. CTLD4 and 5 have carbohydrate-binding ability 55. This 
additional ligand-binding site of sMR can also have an impact on the interaction with 
CD45. Mannosylated oligosaccharides with more than one mannose residue might 
facilitate the clustering of sMR in cell supernatant as well as in serum. This may suggest 
that multiple soluble mannose receptor molecules cooperate in the ligand binding 
process to CD45 120 comparable to complexed FcMR. In contrast, unpublished data from 
Dr. Verena Schütte showed that addition of OVA, a binding partner for CTLD4 of the 
MR, interrupts the interaction of MR with CD45 on CD8+ T cells. This result shows that 
ligand binding by CTLDs and CR domain of the MR is competitively meaning that 
binding of mannosylated proteins to CTLDs can also interrupt interaction with CD45.  
 
 
 
Figure 32: Hypothesis of dimerization of CD45 by cMR, FcMR, or sMR. Cell-bound MR (cMR), 
organized in protein clusters, binds to autonomous homodimerized CD45 and enables strong inhibition 
of CD45 phosphatase activity (left panel). Complexation of FcMR by an anti-human antibody that 
recognized fused human IgG1 Fc part of FcMR enables multimerization. Binding of this FcMR 
complexes to CD45 enhances autonomous homodimerization of CD45 also leading to strong inhibition 
of CD45 phosphatase activity (middle panel). sMR is added as component of cell supernatant and 
without a factor that facilitate complexation of sMR. Independent homodimerization of CD45 is not 
stabilized by sMR why inhibition of CD45 phosphatase activity is not increased (right panel). 
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Another reason for the diverse effect of FcMR and sMR-containing supernatant could be 
the supernatant itself. sMR for our experiments was produced by BM(GM-CSF) cells 
that shed sMR by cleavage of metalloproteases 65. After 4-5 days of culturing MR-positive 
BM(GM-CSF) cells sMR could be detected in the supernatant (Figure 23). 
Subsequently, this supernatant was used to stimulated MR-negative BM(GM-CSF) cells 
to analyze the influence of sMR on these cells. 
The supernatant was collected from wildtype BM(GM-CSF) cells expressing the MR but 
also CD45. During culturing the amount of sMR increased continuously. Due to the 
expression of CD45 in sMR-producing BM(GM-CSF) cells, the sMR might bind in an 
autocrine manner to the MR-positive BM(GM-CSF) cells. Thereby, the sMR-producing 
MR-positiv BM(GM-CSF) cells might be altered by sMR/CD45 interaction as shown by 
altered phosphotyrosine levels of stimulated BM(GM-CSF) cells (Figure 24). Changed 
intracellular pathways in stimulated MR-positive BM(GM-CSF) cells might result in the 
production of additional soluble factors which influence MR-negative BM(GM-CSF) cells 
in a subsequent stimulation with supernatant (Figure 33).   
 
 
Figure 33: Model of the autocrine effect of sMR on sMR-producing MR-positive BM(GM-CSF) 
cells. sMR-containing supernatant was collected after culturing MR-positive BM(GM-CSF) cells for 4-5 
days. In this time, MR-positive BM(GM-CSF) cells generated sMR by cleavage through 
metalloproteases. sMR within the supernatant binds to CD45 of sMR-producing MR-positive BM(GM-
CSF) cells as well as to CD45 of MR-negative BM(GM-CSF) cells in subsequent stimulation. Interaction 
of sMR and CD45 on MR-positive BM(GM-CSF) cells influences sMR-producing MR-positive BM(GM-
CSF) cells triggering the secretion of additional soluble factor. In turn, these factors together with sMR 
stimulate MR-negative BM(GM-CSF) cells in the subsequent incubation resulting in different effects 
compared to stimulation of MR-negative BM(GM-CSF) cells with recombinant MR. 
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Thus, subsequently, the MR-negative BM(GM-CSF) cells are not only influenced by sMR 
but also by additional soluble factor leading to the observed immunstimulatory capacity 
instead of the observed induction of immuntolerance caused by FcMR. The sMR-
containing supernatant was tested for different cytokines (IFN-γ, IL-12, IL-6, IL-10) 
with no difference compared to the cytokine levels of supernatant from MR-deficient 
BM(GM-CSF) cells (data not shown). This analysis covers only a minimal proportion of 
soluble factors secreted by APCs. To circumvent additional effects of soluble factors, 
experiments with purified sMR are essential to verify its effects on BM(GM-CSF) cells 
without  cofactors.  
6.3. CD45 and JAK/STAT signaling in APCs 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway provides a mechanism to translate extracellular signal e.g. cytokines and growth 
factors, into a transcriptional response. Activation of this signal pathway stimulates cell 
proliferation, differentiation, cell migration, and apoptosis. Mutations that constitutively 
activate or inactivate players of this pathway cause inflammatory diseases 121. For 
example, STAT3 has been indicated in several studies to suppress DC maturation and 
activation, and promotes tolerogenic function 106,122–125. Increased STAT3 activation in c-
fes-/- mice leads to impaired inflammatory responses 126. Furthermore, the disruption of 
the STAT3 gene in MΦ results in an abnormal activity concerning polarization of Th1 
responses and increased amounts of secreted inflammatory cytokines in response to 
endotoxin 127. Mice lacking STAT1 are highly sensitive to different viruses such as 
influenza virus, herpes simplex virus, and vesicular stomatitis virus 128–130.  
CD45 is known to negatively regulate JAK/STAT pathway 48. In vitro studies showed that 
CD45-deficient mast cells showed enhanced proliferation in response to IL-3 indicating a 
role of CD45 in the regulation of IL-3 signalling. Irie-Sasaki et al. (2001) revealed that 
CD45 directly interacts and dephosphorylates JAK2. In line with this, in CD45-deficient 
mice hyperphosphorylation of JAK2, STAT3 and STAT5 was detected 48.  
In general, exogenous ligand binding to receptors induces multimerization of receptors, 
which allows transphosphorlyation of associated JAKs. Subsequently, JAK 
phosphorylates STAT molecules that dimerize, enter the nucleus, and activate or repress 
transcriptional processes 121.  The interaction of FcMR with CD45 leads to a diminished 
CD45 phosphatase activity (Figure 17) and elevated phosphotyrosine levels (Figure 
19) in BM(GM-CSF) cells. This observation raised the question whether the MR has an 
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impact on JAK/STAT signaling in BM(GM-CSF) cells or not. We could show that 
mRNA levels of STAT1 were enhanced 4 h after MR stimulation (Figure 20) Target 
genes of STATs are among other suppressors of cytokine signaling (SOCS) proteins that 
act as negative regulator of JAK/STAT pathway 121. In addition, translation of SOCS3 
was strongly enhanced after MR stimulation of BM(GM-CSF) cells (Figure 20). This 
further indicates a correlation between the MR and JAK/STAT signaling. These hints of 
transcriptional regulation by MR has to be further investigated by transcriptome analysis 
in MR-deficient BM(GM-CSF) cells stimulated with FcMR or control. Thus, genes and 
other signaling pathways that facilitate the diminished effector functions of primed 
antigen-specific T cells might be discovered influencing BM(GM-CSF) cell activity. 
Additionally, this analysis can clarify what kind of other molecules or soluble factors are 
responsible for the divers effect of sMR-containing supernatant due to interaction of 
sMR with CD45 during production of the supernatant 
6.1. sMR in disease states 
The cell-bound form of the MR (cMR) binds a wide range of microbial antigens, e.g. 
Candida albicans, Leishmania, Mycobacterium tuberculosis, HIV, and Pneumocytstis carniii, and 
facilitates the clearance of these pathogens 131. Additionally to the cMR, a functional 
soluble form (sMR) is shed by MR-positive cells 66. This shedding is mediated by 
metalloproteases and enhanced during inflammation 65,66. One postulated function of the 
sMR is to carry soluble ligand to areas of active immune response. Martinez-Pomares et 
al. (1996) detected the binding of a chimeric construct comprising the CR domain of the 
MR to cells in the germinal center of lymphoid organs in mice 59. Confirming 
experiments with a chimeric construct of CTLD4-8 of the MR fused to human IgG1 
showed improved binding of MR to P. carinii and enhanced uptake of the pathogen by 
phagocytic cells. However, the uptake was mediated by the interacting of the 
recombinant protein with cellular Fc-receptors 132.  
 
Beside the function in pathogen clearance, an assisting function for pathogen to escape 
the immune response was observed. Shedding of sMR is enhanced by fungi (P. carinii, 
Candida albicans, Aspergillius fumigatus) through binding of β-glucans to dectin-1 66. 
Extracellular P. carinii is coated with sMR and circumvents phagocytosis by MΦs 67. We 
detected the binding of a chimeric construct comprising the CR, FN II and CTLD1-2 
domains of the MR dampen the immune response of T cells through binding to CD45 
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on APCs. This indicates a mechanism how pathogen-enhanced shedding may facilitate 
immune escape. 
In contrast, the addition of supernatant containing sMR to BM(GM-CSF) cells promoted 
immunogenicity of primed T cells. This might be the underlying pathomechanism why 
sMR is enhanced in human serum in various disease states 68. In general, sMR is found in 
serum of mice 65 and human 68 as we also showed in this work (Figure 30 and Figure 
31).  sMR is detectable both in healthy and diseased individuals, but levels are enhanced 
in diseased individuals 68. Serum levels of human sMR correlate with other markers of 
infection and inflammation such as soluble CD136 68. Patients chronically infected with 
HCV and with cirrhosis has significantly higher amounts of sMR in serum than those 
with no or mild fibrosis 133. Furthermore, Rødgaard-Hansen et al. (2014) predict sMR as 
a marker for several disease states such as sepsis and liver disease 68. In  fibrotic processes 
in the liver Kupffer cells have an important role 134. They produce growth factors, 
cytokines, chemokines and metalloproteases that regulate pro- and anti-fibrotic processes 
134,135. Andersen et al. (2014) consider sMR as a marker for the activation of Kupffer cell 
during chronic inflammation 133.  
Analysis of wildtype and MR-deficient mice fed a low-fat diet (LFD) or high-fat diet 
(HFD) revealed that in adipose tissue (AT) of MR-deficient mice subpopulations of MΦs 
were altered (unpublished data). Adipose tissue MΦs (ATMs) are responsible for obesity-
linked inflammation due to secretion of pro-inflammatory cytokines 103. The polarization 
state of ATMs is dynamic regarding the relationship of pro-inflammatory and anti-
inflammatory MΦs. In general, in obese individuals, the amount of CD11c-positive pro-
inflammatory MΦs exceeds the amount of Ym1-positive anti-inflammatory MΦs 136. In 
HFD MR-deficient mice, the amount of CD11c-positiv MΦs is reduced compared to 
wildtype mice. Furthermore, HFD of MR-deficient mice resulted in an enhanced 
recruitment of other immune cells, e.g. eosinophils and neutrophils, in the AT and a 
reduced fat accumulation (unpublished data). We analyzed serum samples of LFD vs. 
HFD mice as well as of lean and obese humans to investigate a correlation of MR 
expression and HFD-induced obesity. Both mice and human sMR levels were enhanced 
after HFD and obesity, respectively (Figure 30 and Figure 31). In vitro, the sMR in cell 
supernatant may provoke an immunstimulatory effect on antigen-specific T cells primed 
by pre-stimulated BM(GM-CSF) cells. In AT, the populations that express high levels of 
MR are anti-inflammatory MΦs 136. The expression of MR in these MΦs is decreased in 
chronically trained mice compared to sedentary mice on HFD 137. The in vivo data 
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reinforce the assumption that sMR correlates to inflammatory processes. However, the 
shedding of sMR is correlated to the expression of cMR 65. It cannot be excluded that 
sMR has no specific function and is rather a biomarker for several diseases due to 
enhanced expression of cMR during inflammation as proposed by Rødgaard-Hansen et 
al. 68. 
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7. Outlook 
The results of the present study highlight a strong effect of the MR on BM(GM-CSF) 
cells by direct interaction with CD45. Still, there are many open questions to be 
answered.  
The first question to be raised is whether a multimerization of MR is important for the 
interaction with CD45. To further elucidate if a crosslinking of MR molecules such as in 
case of cell-bound MR or complexed FcMR is necessary to provoke the observed effect 
on CD45 phosphatase inhibition it is essential to investigate the CD45 phosphatase 
activity in MR-/- BM(GM-CSF) cells stimulated with uncomplexed FcMR. If single FcMR 
molecules will reduce the CD45 phosphatase activity the priming capacity of stimulated 
BM(GM-CSF) cells need to be further analysed by detecting IFN-γ secretion and 
cytotoxicity of primed antigen-specific T cells.  
The addition of supernatant containing sMR to BM(GM-CSF) cells reduced the CD45 
phosphatase activity similar to complexed FcMR, nevertheless, antigen-specific T cells 
primed by these BM(GM-CSF) cells showed contrary effector functions. To investigate if 
these results are based on other molecules present in the supernatant the experiments 
need to be repeated with purified sMR. To this end, an assay needs to be established to 
isolate sMR from cell supernatant by affinity chromatography. If one is able to isolate 
sMR, experiments can be performed to further elucidate if incubation of BM(GM-CSF) 
cells with sMR results in diminished effector functions of primed antigen-specific T cells 
similar to complexed FcMR. Furthermore, sMR should be isolated from murine serum 
to investigate its influence on BM(GM-CSF) cells as a second source of naturally 
produced sMR and to further elucidate the function of sMR in vivo.  
Beside the CR domain of MR that mediated the interaction with CD45 sMR also 
comprise CTLD4-8 and, thereby, has a second ligand-binding site. It is essential to 
perform competition experiments to investigate if the binding of a second ligand with 
CTLDs increase or inhibit binding capacity of MR to CD45. To this end, co-
immunoprecipitation experiments need to be done with MR-/- BM(GM-CSF) cells 
stimulated with isolated sMR in the presence or absence of CTLD ligands (e.g. OVA or 
mannan). Furthermore, CD45 phosphatase activity assay with these stimulated BM(GM-
CSF) cells should be performed.  
The incubation of BM(GM-CSF) cells with either FcMR or sMR resulted in a slightly 
increase of total phosphotyrosine proteins in these cells indicating an influence of MR on 
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intracellular processes of BM(GM-CSF) cells. So, of extraordinary interest is the effect of 
MR on signalling pathways and metabolic processes in BM(GM-CSF) cells. Therefor, it is 
important to investigate transcriptional reprogramming in BM(GM-CSF) cells by 
transcriptome analysis of MR-stimulated BM(GM-CSF) cells. Thus, a MR-mediated 
influence on JAK/STAT pathway might be confirmed and connected or other involved 
intracellular processes can be discovered. To further clarify the role of serum sMR in 
HFD and obesity co-culture experiments should be performed with sMR-treated 
BM(GM-CSF) cells and adipocytes. Equally, it is essential to investigate a direct influence 
of sMR on adipocytes by analysing lipid metabolism of MR-treated adipocytes.   
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9. Abbreviations 
°C Degree Celsius 
4-NPP 4-Nitrophenyl phosphate disodium salt hexahydrate 
ABTS 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
APC Antigen presenting cell 
APS Ammonium persulfate 
AT Adipose tissue 
ATM Adipose tissue macrophage 
BBS Borate buffered saline 
BCA Bicinchoninic acid 
Bcl-6 B-cell lymphoma 6 protein 
BCR B cell receptor 
BM Bone marrow 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CFSE Carboxyfluorescein succinimidyl ester 
CHO Chinese hamster ovary 
cMR Cellular MR 
CR Cysteine-rich 
Csk C-src tyrosine kinase 
CTL Cytotoxic T cell 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 
CTLD C-type lectin-like domain 
Ctrl Control 
DC Dendritic cell 
DMEM Dulbecco’s modified eagle’s medium 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EAE Experimental autoimmune encephalomyelitis 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
FACS Fluorescence-activated cell sorting 
FcMR Recombinant MR construct comprising the CR, FN II, and 
CTLD1-2 domains of the MR 
FCS Fetal calf serum 
FN  Fibronectin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
h, min, sec Hours, minutes, seconds 
Hck Tyrosine-protein kinase Hck 
HCV Hepatitis C virus 
Abbreviations 
 
 87 
HEK Human Embryonic Kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFD High-fat diet 
HPRT Hypoxanthine phosphoribosyltransferase 
HRP Horseradish peroxidase 
IFN Interferon 
IgG, IgE Immunoglobulin G, immunoglobulin E 
IL Interleukin 
IMDM Iscove’s modified 87ulbecco’s medium 
IP Immunoprezipitation 
ITAM Immunoreceptor tyrosine-base activation motif 
JAK Janus kinase 
kDa Kilodalton 
LAT Linker of activated T cells 
LB Laemmli buffer 
Lck Lymphocyte-specific protein tyrosine kinase 
LFD Low-fat diet 
LPS Lipopolysaccharide 
LSEC Liver sinusoidal endothelial cell 
Lyn Tyrosine-protein kinase Lyn 
LYP Lymphoid-tyrosine phosphatase 
M-CSF Macrophage colony-stimulating factor 
mA Milliampere 
MAPK Mitogen-activated protein kinase 
MGL Macrophage galactose-type lectin 
MHC Major histocompatibility complex 
MIIC MHC class II-rich compartment 
MR Mannose receptor 
MR-/-, CD45-/-, c-fes-/- MR-, CD45-, c-fes-deficient 
mRNA Messenger RNA 
MΦ Macrophage 
NAFLD Non-alcoholic fatty liver disease 
NaPOX NeutrAvidin horseradish peroxidase 
NASH Non-alcoholic steatohepatitis 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK Natural killer 
nm, µm, mm, cm Nano-, micro-, milli-, centimeter 
nM, µM, mM, M Nano-, micro-, milli-, Molar 
O/N Overnight 
OD Optical density 
OVA Ovalbumin 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline 
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PBST Phosphate buffered saline with Tween 
PD-L1, PD-L2 Programmed death-ligand 1 and 2 
pg, ng, µg, mg Pico-, nano-, micro-, milligram 
PNGase F Peptide N-glycanase F 
PPIA Peptidylprolyl isomerase A 
PRR Pattern recognition receptor 
PTK Protein tyrosine kinase 
PTP Protein tyrosine phosphatase 
qRT-PCR Quantitative Real-time polymerase chain reaction 
rcf Relative centrifugal force 
RNA Ribonucleic acid 
RPMI Roswell park memorial institute medium 
RT Room temperature 
SCID Severe-combined immunodeficiency 
SDS Sodium dodecyl sulfate 
SEE Stable early endosome 
SEM Standard error of the mean 
SFK Src family protein tyrosine kinases 
SH2 Src homology 2 
SHP-1 Src homology region 2 domain-containing phosphatase-1 
SLE Systemic lupus erythematosus 
SLIT Sublingual immunotherapy 
SLP-76 SH2 domain containing leukocyte protein of 76 kDa 
sMR Soluble MR 
SOCS Suppressor of cytokine signaling 
STAT Signal transducer and activator of transcription protein 
TBP TATA-box binding protein 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween 
TCR T cell receptor 
TEA Triethanolamine 
TEMED Tetramethylethylenediamine 
TFH T follicular-helper cell 
Th1, Th2, Th9, Th17 T helper 1, T helper 2, T helper 9, T helper 17 cell 
TLR Toll-like receptor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
Treg T-regulatory cell 
Trf Transferrin 
V Volt 
v/v Volume to volume 
W Watt 
w/, w/o With, without 
w/v Weight to volume 
wt Wildtype 
Abbreviations 
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ZAP-70 Zeta-chain-associated protein kinase 70 
µL, mL, L Micro-, milli-, liter 
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